<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EMEND- aprepitantÂ capsuleÂ </strong><br>Rebel Distributors Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND.<br><br>EMEND (aprepitant) Capsules<br>Initial U.S. Approval: 2003</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">EMEND<span class="Sup">Â®</span> is a substanceÂ P/neurokininÂ 1 (NK<span class="Sub">1</span>) receptor antagonist, indicated: </p>
<ul>
<li>in combination with other antiemetic agents for the: <ul>
<li>prevention of acute and delayed <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin (<a href="#i4i_section_id_1c2f425a-ae81-444a-861b-e40c24798d47">1.1</a>)</li>
<li>prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) (<a href="#i4i_section_id_1c2f425a-ae81-444a-861b-e40c24798d47">1.1</a>) </li>
</ul>
</li>
<li>for the prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (PONV) (<a href="#i4i_section_id_04dd851b-e324-45d2-b840-53add9f4c232">1.2</a>) </li>
</ul>
<p class="Highlighta">Limitations of Use (<a href="#i4i_section_id_b3f81b2b-692c-41a8-9f10-54651ad65f1a">1.3</a>) </p>
<ul>
<li>Not studied for the treatment of established <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </li>
<li>Chronic continuous administration is not recommended. </li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Prevention of Chemotherapy Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (<a href="#i4i_section_id_4d51ebb6-20d4-49a7-ab39-ea6c92216e71">2.1</a>) </p>
<ul><li>EMEND is given for 3Â days as part of the chemotherapy induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (CINV) regimen that includes a corticosteroid and a 5-HT<span class="Sub">3</span> antagonist. (<a href="#i4i_section_id_4d51ebb6-20d4-49a7-ab39-ea6c92216e71">2.1</a>) <ul>
<li>The recommended dose of EMEND is 125Â mg orally 1Â hour prior to chemotherapy treatment (DayÂ 1) and 80Â mg orally once daily in the morning on DaysÂ 2 and 3. (<a href="#i4i_section_id_4d51ebb6-20d4-49a7-ab39-ea6c92216e71">2.1</a>) </li>
<li>EMEND (fosaprepitant dimeglumine) for Injection may be substituted for oral EMEND (125 mg) on Day 1 only as part of the CINV regimen. (<a href="#i4i_section_id_4d51ebb6-20d4-49a7-ab39-ea6c92216e71">2.1</a>) </li>
</ul>
</li></ul>
<p class="Highlighta">Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (<a href="#i4i_section_id_e5c89dbb-8bfb-4701-a606-4d327149c923">2.2</a>) </p>
<ul><li>The recommended oral dosage of EMEND for the <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (PONV) indication is 40Â mg within 3Â hours prior to induction of anesthesia. (<a href="#i4i_section_id_e5c89dbb-8bfb-4701-a606-4d327149c923">2.2</a>) </li></ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules: 40Â mg; 80Â mg; 125Â mg (<a href="#i4i_dosage_form_strength_id_9e0a6b7a-4843-4131-aa95-2afd0c6503a1">3</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication. (<a href="#i4i_contraindications_id_496b9c54-2ac9-4b1e-85a9-e907309d4432">4</a>, <a href="#i4i_section_id_8497119c-f7c1-4c11-8dd1-935a96d18161">6.2</a>)</li>
<li>EMEND should not be used concurrently with pimozide, terfenadine, astemizole, or cisapride, since inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions. (<a href="#i4i_contraindications_id_496b9c54-2ac9-4b1e-85a9-e907309d4432">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Coadministration of aprepitant with warfarin (a CYP2C9 substrate) may result in a clinically significant decrease in International Normalized Ratio (INR) of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. (<a href="#i4i_section_id_648cc88d-9073-4262-9402-f25d32304927">5.2</a>)</li>
<li>The efficacy of hormonal contraceptives during and for 28Â days following the last dose of EMEND may be reduced. Alternative or back-up methods of contraception should be used. (<a href="#i4i_section_id_acfe2236-28db-43a6-ba45-4543b6189efb">5.3</a>, <a href="#i4i_section_id_807cf647-b0d3-4534-8919-4519f8a90768">7.1</a>)</li>
<li>EMEND is a dose-dependent inhibitor of CYP3A4, and should be used with caution in patients receiving concomitant medications that are primarily metabolized through CYP3A4. (<a href="#i4i_section_id_1df42ccc-01db-4c01-bc2d-f3e5b46b7474">5.1</a>)</li>
<li>Caution should be exercised when administered in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#i4i_section_id_83128f78-c9e6-4e39-a8dd-ac83feaee0b3">2.5</a>, <a href="#i4i_section_id_30ea6ad6-04ae-4309-a8a1-625600d1f919">5.4</a>, <a href="#i4i_pharmacokinetics_id_23b615f3-edc9-4948-8d83-3cc71cd09989">12.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>Clinical adverse experiences for the CINV regimen in conjunction with highly and moderately emetogenic chemotherapy (incidence &gt;10%) are: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. (<a href="#i4i_section_id_16a557a3-f981-47ce-9173-a561e71e1b9a">6.1</a>)</li>
<li>Clinical adverse experiences for the PONV regimen (incidence &gt;5%) are: <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>. (<a href="#i4i_section_id_16a557a3-f981-47ce-9173-a561e71e1b9a">6.1</a>)</li>
</ul>
<p class="Highlighta"><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Aprepitant is a substrate for CYP3A4; therefore, coadministration of EMEND with drugs that inhibit or induce CYP3A4 activity may result in increased or reduced plasma concentrations of aprepitant, respectively. (<a href="#i4i_section_id_1df42ccc-01db-4c01-bc2d-f3e5b46b7474">5.1</a>, <a href="#i4i_section_id_807cf647-b0d3-4534-8919-4519f8a90768">7.1</a>, <a href="#i4i_section_id_37c4ac6d-aabe-486e-902f-9a2c189c57c1">7.2</a>). </li>
<li>Aprepitant is an inducer of CYP2C9; therefore, coadministration of EMEND with drugs that are metabolized by CYP2C9 (e.g. warfarin, tolbutamide), may result in lower plasma concentrations of these drugs. (<a href="#i4i_section_id_648cc88d-9073-4262-9402-f25d32304927">5.2</a>, <a href="#i4i_section_id_807cf647-b0d3-4534-8919-4519f8a90768">7.1</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 3/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Prevention of Chemotherapy Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (CINV)</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (PONV)</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Prevention of Chemotherapy Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (CINV)</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (PONV)</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Geriatric Patients</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Coadministration with Other Drugs</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 CYP3A4 Interactions</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Coadministration with Warfarin (a CYP2C9 substrate)</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Coadministration with Hormonal Contraceptives</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Patients with Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Chronic Continuous Use</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Effect of Aprepitant on the Pharmacokinetics of Other Agents</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Effect of Other Agents on the Pharmacokinetics of Aprepitant</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Additional Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Prevention of Chemotherapy Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (CINV)</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (PONV)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Instructions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_452db844-6428-4576-a88a-8204015b0680"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1c2f425a-ae81-444a-861b-e40c24798d47"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Prevention of Chemotherapy Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (CINV)</h2>
<p class="First">EMEND<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a>, in combination with other antiemetic agents, is indicated for the:</p>
<ul>
<li>prevention of acute and delayed <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin</li>
<li>prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) <span class="Italics">[see <a href="#i4i_section_id_4d51ebb6-20d4-49a7-ab39-ea6c92216e71">Dosage and Administration (2.1)</a>]</span>.</li>
</ul>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd><p class="First">Registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>Copyright Â© 2003, 2005, 2006 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All Rights Reserved</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_04dd851b-e324-45d2-b840-53add9f4c232"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (PONV)</h2>
<p class="First">EMEND is indicated for the prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <span class="Italics">[see <a href="#i4i_section_id_e5c89dbb-8bfb-4701-a606-4d327149c923">Dosage and Administration (2.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3f81b2b-692c-41a8-9f10-54651ad65f1a"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Limitations of Use</h2>
<p class="First">EMEND has not been studied for the treatment of established <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Chronic continuous administration is not recommended <span class="Italics">[see <a href="#i4i_section_id_6eb6f12c-369d-40b7-a543-a26d331769f1">Warnings and Precautions (5.5)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_50299883-eccd-4fd1-b55c-70cd968ff210"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4d51ebb6-20d4-49a7-ab39-ea6c92216e71"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Prevention of Chemotherapy Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (CINV)</h2>
<p class="First">Capsules of EMEND (aprepitant) are given for 3Â days as part of a regimen that includes a corticosteroid and a 5-HT<span class="Sub">3</span> antagonist. The recommended dose of EMEND is 125Â mg orally 1Â hour prior to chemotherapy treatment (DayÂ 1) and 80Â mg orally once daily in the morning on DaysÂ 2 and 3. </p>
<p>EMEND may be taken with or without food.</p>
<p>EMEND (fosaprepitant dimeglumine) for Injection (115Â mg) is a prodrug of aprepitant and may be substituted for oral EMEND (125 mg), 30 minutes prior to chemotherapy, on Day 1 only of the CINV regimen as an intravenous infusion administered over 15 minutes.</p>
<p>In clinical studies with EMEND, the following regimen was used for the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with highly emetogenic cancer chemotherapy:</p>
<a name="id_3207cf6d-5242-4bc7-981f-8f44438be59f"></a><table width="599.000">
<col width="24.4%">
<col align="center" width="20.5%">
<col align="center" width="18.4%">
<col align="center" width="18.4%">
<col align="center" width="18.4%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">Day 1</td>
<td class="Botrule" align="center" valign="top">Day 2</td>
<td class="Botrule" align="center" valign="top">Day 3</td>
<td class="Botrule" align="center" valign="top">Day 4</td>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>EMEND was administered orally 1 hour prior to chemotherapy treatment on Day 1 and in the morning on Days 2 and 3.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€ </a></dt>
<dd>Dexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. The dose of dexamethasone was chosen to account for drug interactions.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">â€¡</a></dt>
<dd>Ondansetron was administered 30 minutes prior to chemotherapy treatment on Day 1.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">EMEND<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="top">125 mg orally</td>
<td class="Botrule" align="center" valign="top">80 mg orally</td>
<td class="Botrule" align="center" valign="top">80 mg orally</td>
<td class="Botrule" align="center" valign="top">none</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Dexamethasone<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€ </a>
</td>
<td class="Botrule" align="center" valign="top">12 mg orally</td>
<td class="Botrule" align="center" valign="top">8 mg orally </td>
<td class="Botrule" align="center" valign="top">8 mg orally</td>
<td class="Botrule" align="center" valign="top">8 mg orally</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Ondansetron<a name="footnote-reference-4" href="#footnote-4" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="top">32 mg I.V.</td>
<td class="Botrule" align="center" valign="top">none</td>
<td class="Botrule" align="center" valign="top">none</td>
<td class="Botrule" align="center" valign="top">none</td>
</tr>
</tbody>
</table>
<p>In a clinical study with EMEND, the following regimen was used for the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with moderately emetogenic cancer chemotherapy:</p>
<a name="id_9d05229f-3bf1-47f3-9c9b-d260567ddc84"></a><table width="642.000">
<col width="36.8%">
<col align="center" width="22.3%">
<col align="center" width="19.6%">
<col align="center" width="21.3%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">Day 1</td>
<td class="Botrule" align="center" valign="top">Day 2</td>
<td class="Botrule" align="center" valign="top">Day 3</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>EMEND was administered orally 1 hour prior to chemotherapy treatment on Day 1 and in the morning on Days 2 and 3.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">â€ </a></dt>
<dd>Dexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone was chosen to account for drug interactions.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">â€¡</a></dt>
<dd>Ondansetron 8-mg capsule was administered 30 to 60 minutes prior to chemotherapy treatment and one 8-mg capsule was administered 8 hours after the first dose on Day 1.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">EMEND<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="top">125 mg orally</td>
<td class="Botrule" align="center" valign="top">80 mg orally</td>
<td class="Botrule" align="center" valign="top">80 mg orally</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Dexamethasone<a name="footnote-reference-6" href="#footnote-6" class="Sup">â€ </a>
</td>
<td class="Botrule" align="center" valign="top">12 mg orally</td>
<td class="Botrule" align="center" valign="top">none</td>
<td class="Botrule" align="center" valign="top">none</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Ondansetron<a name="footnote-reference-7" href="#footnote-7" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="center" valign="top">2 x 8 mg orally </td>
<td class="Botrule" align="center" valign="top">none</td>
<td class="Botrule" align="center" valign="top">none</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e5c89dbb-8bfb-4701-a606-4d327149c923"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (PONV)</h2>
<p class="First">The recommended oral dosage of EMEND is 40 mg within 3 hours prior to induction of anesthesia.</p>
<p>EMEND may be taken with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e747f913-a4fa-46ba-8a1c-eb0e129c9585"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Geriatric Patients</h2>
<p class="First">No dosage adjustment is necessary for the elderly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a4998f9f-3018-48b9-884d-6c5ee1ed0298"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dosage adjustment is necessary for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or for patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) undergoing hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_83128f78-c9e6-4e39-a8dd-ac83feaee0b3"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dosage adjustment is necessary for patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 5 to 9). There are no clinical data in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score &gt;9).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8365f5a2-465d-4f9a-b256-d0cb861bebfc"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Coadministration with Other Drugs</h2>
<p class="First">For additional information on dose adjustment for corticosteroids when coadministered with EMEND, see <span class="Italics"><a href="#i4i_section_id_807cf647-b0d3-4534-8919-4519f8a90768">Drug Interactions (7.1)</a></span>.</p>
<p>Refer to the full prescribing information for coadministered antiemetic agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_9e0a6b7a-4843-4131-aa95-2afd0c6503a1"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>Capsules EMEND 40Â mg are opaque, hard, gelatin capsules, with white body and mustard yellow cap withÂ â€œ464â€? and â€œ40 mgâ€? printed radially in black ink on the body.</li>
<li>Capsules EMEND 80Â mg are white, opaque, hard, gelatin capsules, withÂ â€œ461â€? and â€œ80 mgâ€? printed radially in black ink on the body.</li>
<li>Capsules EMEND 125Â mg are opaque, hard, gelatin capsules, with white body and pink cap withÂ â€œ462â€? and â€œ125 mgâ€? printed radially in black ink on the body.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_496b9c54-2ac9-4b1e-85a9-e907309d4432"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">EMEND is contraindicated in patients who are hypersensitive to any component of the product.</p>
<p>EMEND is a dose-dependent inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A4). EMEND should not be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions <span class="Italics">[see <a href="#i4i_section_id_807cf647-b0d3-4534-8919-4519f8a90768">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_999aab6d-7353-40ae-9e9e-932f286f1d5b"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1df42ccc-01db-4c01-bc2d-f3e5b46b7474"></a><a name="section-5.1"></a><p></p>
<h2>5.1 CYP3A4 Interactions</h2>
<p class="First"> EMEND (aprepitant), a dose-dependent inhibitor of CYP3A4, should be used with caution in patients receiving concomitant medications that are primarily metabolized through CYP3A4. Moderate inhibition of CYP3A4 by aprepitant, 125Â mg/80Â mg regimen, could result in elevated plasma concentrations of these concomitant medications. </p>
<p> Weak inhibition of CYP3A4 by a single 40Â mg dose of aprepitant is not expected to alter the plasma concentrations of concomitant medications that are primarily metabolized through CYP3A4 to a clinically significant degree. </p>
<p> When aprepitant is used concomitantly with another CYP3A4 inhibitor, aprepitant plasma concentrations could be elevated. When EMEND is used concomitantly with medications that induce CYP3A4 activity, aprepitant plasma concentrations could be reduced and this may result in decreased efficacy of EMEND <span class="Italics">[see <a href="#i4i_section_id_807cf647-b0d3-4534-8919-4519f8a90768">Drug Interactions (7.1)</a>]</span>. </p>
<p>Chemotherapy agents that are known to be metabolized by CYP3A4 include docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine and vincristine. In clinical studies, EMEND (125Â mg/80Â mg regimen) was administered commonly with etoposide, vinorelbine, or paclitaxel. The doses of these agents were not adjusted to account for potential drug interactions.</p>
<p>In separate pharmacokinetic studies no clinically significant change in docetaxel or vinorelbine pharmacokinetics was observed when EMEND (125Â mg/80Â mg regimen) was co-administered.</p>
<p>Due to the small number of patients in clinical studies who received the CYP3A4 substrates vinblastine, vincristine, or ifosfamide, particular caution and careful monitoring are advised in patients receiving these agents or other chemotherapy agents metabolized primarily by CYP3A4 that were not studied <span class="Italics">[see <a href="#i4i_section_id_807cf647-b0d3-4534-8919-4519f8a90768">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_648cc88d-9073-4262-9402-f25d32304927"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Coadministration with Warfarin (a CYP2C9 substrate)</h2>
<p class="First">Coadministration of EMEND with warfarin may result in a clinically significant decrease in International Normalized Ratio (INR) of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. In patients on chronic warfarin therapy, the INR should be closely monitored in the 2-week period, particularly at 7 to 10Â days, following initiation of the 3-day regimen of EMEND with each chemotherapy cycle, or following administration of a single 40Â mg dose of EMEND for the prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <span class="Italics">[see <a href="#i4i_section_id_807cf647-b0d3-4534-8919-4519f8a90768">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_acfe2236-28db-43a6-ba45-4543b6189efb"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Coadministration with Hormonal Contraceptives</h2>
<p class="First">Upon coadministration with EMEND, the efficacy of hormonal contraceptives during and for 28Â days following the last dose of EMEND may be reduced. Alternative or back-up methods of contraception should be used during treatment with EMEND and for 1Â month following the last dose of EMEND <span class="Italics">[see <a href="#i4i_section_id_807cf647-b0d3-4534-8919-4519f8a90768">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_30ea6ad6-04ae-4309-a8a1-625600d1f919"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Patients with Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">There are no clinical or pharmacokinetic data in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score &gt;9). Therefore, caution should be exercised when EMEND is administered in these patients <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_23b615f3-edc9-4948-8d83-3cc71cd09989">Clinical Pharmacology (12.3)</a> and <a href="#i4i_section_id_83128f78-c9e6-4e39-a8dd-ac83feaee0b3">Dosage and Administration (2.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6eb6f12c-369d-40b7-a543-a26d331769f1"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Chronic Continuous Use</h2>
<p class="First">Chronic continuous use of EMEND for prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> is not recommended because it has not been studied; and because the drug interaction profile may change during chronic continuous use.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_dc8d4562-28a2-442e-9a74-b4d0cdc8b4ef"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The overall safety of aprepitant was evaluated in approximately 5300Â individuals.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_16a557a3-f981-47ce-9173-a561e71e1b9a"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><span class="Italics">Chemotherapy Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></p>
<p><span class="Italics">Highly Emetogenic Chemotherapy</span></p>
<p>In 2 well-controlled clinical trials in patients receiving highly emetogenic cancer chemotherapy, 544 patients were treated with aprepitant during Cycle 1 of chemotherapy and 413 of these patients continued into the Multiple-Cycle extension for up to 6 cycles of chemotherapy. EMEND was given in combination with ondansetron and dexamethasone.</p>
<p>In Cycle 1, clinical adverse experiences were reported in approximately 69% of patients treated with the aprepitant regimen compared with approximately 68% of patients treated with standard therapy. Table 1 shows the percent of patients with clinical adverse experiences reported at an incidence â‰¥3%.</p>
<a name="id_1480bfbd-41d6-4a33-bcfb-5cf689213637"></a><table width="670.000">
<caption><span>Table 1: Percent of Patients Receiving Highly Emetogenic Chemotherapy with Clinical Adverse Experiences (Incidence â‰¥3%) â€” Cycle 1</span></caption>
<col width="42.7%">
<col width="28.7%">
<col width="28.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">Aprepitant Regimen<br>(N = 544)</td>
<td class="Botrule" align="center" valign="top">Standard Therapy<br>(N = 550)</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Body as a Whole/Site Unspecified</span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top">
<p class="First">Â Â <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="4318379" conceptname="Disorder of mucous membrane">Mucous Membrane Disorder</span></p>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">17.8</p>
<p>6.6</p>
<p>5.9</p>
<p>4.6</p>
<p>2.9</p>
<p>2.6</p>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">11.8</p>
<p>4.4</p>
<p>5.1</p>
<p>3.3</p>
<p>3.5</p>
<p>3.1</p>
</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Italics"><span class="Bold">Digestive System</span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top">
<p class="First">Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">Epigastric Discomfort</span></p>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">12.7</p>
<p>10.3</p>
<p>10.3</p>
<p>7.5</p>
<p>5.3</p>
<p>4.2</p>
<p>4.0</p>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">11.8</p>
<p>12.2</p>
<p>7.5</p>
<p>7.6</p>
<p>4.9</p>
<p>3.1</p>
<p>3.1</p>
</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Eyes, Ears, Nose, and Throat</span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">3.7</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">3.8</p></td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Hemic and Lymphatic System</span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">3.1</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">2.9</p></td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Metabolism and Nutrition</span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">10.1</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">9.5</p></td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Nervous System </span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top">
<p class="First">Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">8.5</p>
<p>2.9</p>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">8.7</p>
<p>3.1</p>
</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Respiratory System </span></span></td></tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccups</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">10.8</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">5.6</p></td>
</tr>
</tbody>
</table>
<p>In addition, isolated cases of serious adverse experiences, regardless of causality, of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and perforating <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> were reported in highly emetogenic CINV clinical studies.</p>
<p><span class="Italics">Moderately Emetogenic Chemotherapy</span></p>
<p>During CycleÂ 1 of 2 moderately emetogenic chemotherapy studies, 868 patients were treated with the aprepitant regimen and 686 of these patients continued into extensions for up to 4 cycles of chemotherapy. In the combined analysis of CycleÂ 1 data for these 2 studies, adverse experiences were reported in approximately 69% of patients treated with the aprepitant regimen compared with approximately 72% of patients treated with standard therapy.</p>
<p>In the combined analysis of CycleÂ 1 data for these 2 studies, the adverse experience profile in both moderately emetogenic chemotherapy studies was generally comparable to the highly emetogenic chemotherapy studies. TableÂ 2 shows the percent of patients with clinical adverse experiences reported at an incidence â‰¥3%.</p>
<a name="id_7b757400-a32d-4757-836b-ab81a82a53f8"></a><table width="670.000">
<caption><span>Table 2: Percent of Patients Receiving Moderately Emetogenic Chemotherapy with Clinical Adverse Experiences (Incidence â‰¥3%) â€” Cycle 1</span></caption>
<col width="35.2%">
<col width="30.3%">
<col width="34.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">Aprepitant Regimen <br>(N = 868)</td>
<td class="Botrule" align="center" valign="top">Standard Therapy <br>(N = 846)</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Blood and Lymphatic System Disorders </span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">5.8</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">5.6</p></td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Metabolism and Nutrition Disorders</span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">6.2</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">7.2</p></td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Italics"><span class="Bold">Psychiatric Disorders</span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">2.6</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">3.7</p></td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top">
<p class="First">Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">13.2</p>
<p>2.8</p>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">14.3</p>
<p>3.4</p>
</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top">
<p class="First">Â Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></p>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">10.3</p>
<p>7.6</p>
<p>5.8</p>
<p>5.8</p>
<p>3.1</p>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">15.5</p>
<p>8.7</p>
<p>3.8</p>
<p>5.1</p>
<p>2.7</p>
</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Skin and Subcutaneous Tissue Disorders </span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">12.4</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">11.9</p></td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">General Disorders and General Administration Site Conditions</span></span></td></tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">
<p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">15.4</p>
<p>4.7</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">15.6</p>
<p>4.6</p>
</td>
</tr>
</tbody>
</table>
<p>In a combined analysis of these two studies, isolated cases of serious adverse experiences were similar in the two treatment groups.</p>
<p><span class="Italics">Highly and Moderately Emetogenic Chemotherapy</span></p>
<p>The following additional clinical adverse experiences (incidence &gt;0.5% and greater than standard therapy), regardless of causality, were reported in patients treated with aprepitant regimen in either HEC or MEC studies:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>: </span><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>, herpes simplex, lower <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>,Â <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>. </p>
<p><span class="Italics">Neoplasms benign, malignant and unspecified (including <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> and <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span>):</span> malignant neoplasm, non-small cell lung carcinoma.</p>
<p><span class="Italics">Blood and lymphatic system disorders:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Italics">Metabolism and nutrition disorders:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite decreased</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p><span class="Italics">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">anxiety disorder</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Italics">Nervous system:</span> <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">sensory neuropathy</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>: </span><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span> deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p><span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, nasal secretion, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span>, vocal disturbance.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: </span><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, acid reflux, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">deglutition disorder</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">obstipation</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> increased.</p>
<p><span class="Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. </p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p><span class="Italics">Renal and urinary disorders: </span><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<p><span class="Italics">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>.</p>
<p><span class="Italics">General disorders and administrative site conditions: </span><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>.</p>
<p><span class="Italics">Investigations:</span> <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> was reported as a serious adverse experience in a patient receiving aprepitant with cancer chemotherapy in another CINV study.</p>
<p><span class="Italics">Laboratory Adverse Experiences</span></p>
<p>Table 3 shows the percent of patients with laboratory adverse experiences reported at an incidence â‰¥3% in patients receiving highly emetogenic chemotherapy.</p>
<a name="id_d02dd83b-f523-4f7c-bf43-e23a8f6f971f"></a><table width="654.000">
<caption><span>Table 3: Percent of Patients Receiving Highly Emetogenic Chemotherapy with Laboratory Adverse Experiences (Incidence â‰¥3%) â€” Cycle 1</span></caption>
<col width="42.8%">
<col align="center" width="28.6%">
<col align="center" width="28.6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">Aprepitant Regimen<br>(N = 544)</td>
<td class="Botrule" align="center" valign="top">Standard Therapy<br>(N = 550)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></p>
<p>ALT Increased</p>
<p>Blood Urea Nitrogen Increased</p>
<p>Serum Creatinine Increased</p>
<p>AST Increased</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">6.8</p>
<p>6.0</p>
<p>4.7</p>
<p>3.7</p>
<p>3.0</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">5.3</p>
<p>4.3</p>
<p>3.5</p>
<p>4.3</p>
<p>1.3</p>
</td>
</tr>
</tbody>
</table>
<p>The following additional laboratory adverse experiences (incidence &gt;0.5% and greater than standard therapy), regardless of causality, were reported in patients treated with aprepitant regimen: alkaline phosphatase increased, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, leukocytes increased, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">erythrocyturia</span>, leukocyturia.</p>
<p>The adverse experience profiles in the Multiple-Cycle extensions of HEC and MEC studies for up to 6Â cycles of chemotherapy were generally similar to that observed in CycleÂ 1.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></p>
<p>In well-controlled clinical studies in patients receiving general anesthesia, 564Â patients were administered 40Â mg aprepitant orally and 538Â patients were administered 4Â mg ondansetronÂ IV.</p>
<p>Clinical adverse experiences were reported in approximately 60% of patients treated with 40Â mg aprepitant compared with approximately 64% of patients treated with 4Â mg ondansetronÂ IV. TableÂ 4 shows the percent of patients with clinical adverse experiences reported at an incidence â‰¥3% of the combined studies.</p>
<a name="id_a0af9e45-46da-4ba6-8be3-01384c6fc798"></a><table width="627.000">
<caption><span>Table 4: Percent of Patients Receiving General Anesthesia with Clinical Adverse Experiences (Incidence â‰¥3%)</span></caption>
<col width="45.6%">
<col width="26.3%">
<col width="28.1%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">Aprepitant 40 mg<br> (N = 564)</td>
<td class="Botrule" align="center" valign="top">Ondansetron<br> (N = 538)</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></p></td>
<td class="Botrule" align="center" valign="top">2.3</td>
<td class="Botrule" align="center" valign="top">3.2</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Blood and Lymphatic System Disorders</span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Botrule" align="center" valign="top">3.0</td>
<td class="Botrule" align="center" valign="top">4.3</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Psychiatric Disorders</span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule" align="center" valign="top">2.1</td>
<td class="Botrule" align="center" valign="top">3.3</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule" align="center" valign="top">5.0</td>
<td class="Botrule" align="center" valign="top">6.5</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Italics"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></p></td>
<td class="Botrule" align="center" valign="top">4.4</td>
<td class="Botrule" align="center" valign="top">3.9</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Italics"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top">
<p class="First">Â Â <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">5.7</p>
<p>2.1</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">4.6</p>
<p>3.2</p>
</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top">
<p class="First">Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p>
<p>Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">8.5</p>
<p>8.5</p>
<p>4.1</p>
<p>2.5</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">8.6</p>
<p>7.6</p>
<p>5.8</p>
<p>3.9</p>
</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">Skin and Subcutaneous Tissue Disorders</span></span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule" align="center" valign="top">7.6</td>
<td class="Botrule" align="center" valign="top">8.4</td>
</tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="Italics">General Disorders and General Administration Site Conditions</span></span></td></tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule" align="center" valign="top">5.9</td>
<td class="Botrule" align="center" valign="top">10.6</td>
</tr>
</tbody>
</table>
<p>The following additional clinical adverse experiences (incidence &gt;0.5% and greater than ondansetron), regardless of causality, were reported in patients treated with aprepitant: </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infection</span></p>
<p><span class="Italics">Metabolism and nutrition disorders:</span> <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span></p>
<p><span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>.</p>
<p><span class="Italics">Skin and subcutaneous tissue disorders: </span><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Italics">General disorders and administrative site conditions: </span> <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Italics">Investigations: </span> <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">blood pressure decreased</span> </p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications:</span> <span class="product-label-link" type="condition" conceptid="4308716" conceptname="Intraoperative hemorrhage">operative hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="439981" conceptname="Wound dehiscence">wound dehiscence</span>.</p>
<p>Other adverse experiences (incidence â‰¤0.5%) reported in patients treated with aprepitant 40 mg for <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> included: </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbance</span>. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">visual acuity reduced</span>.</p>
<p><span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>: </span><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: </span><span class="product-label-link" type="condition" conceptid="197377" conceptname="Abnormal bowel sounds">bowel sounds abnormal</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>.</p>
<p>There were no serious adverse drug-related experiences reported in the <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> clinical studies in patients taking 40 mg aprepitant.</p>
<p><span class="Italics">Laboratory Adverse Experiences</span></p>
<p>One laboratory adverse experience, <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">hemoglobin decreased</span> (40 mg aprepitant 3.8%, ondansetron 4.2%), was reported at an incidence â‰¥3% in a patient receiving general anesthesia. </p>
<p>The following additional laboratory adverse experiences (incidence &gt;0.5% and greater than ondansetron), regardless of causality, were reported in patients treated with aprepitant 40 mg: blood albumin decreased, blood bilirubin increased, blood glucose increased, <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> decreased, glucose urine present.</p>
<p> The adverse experience of ALT increased occurred with similar incidence in patients treated with aprepitant 40 mg (1.1%) as in patients treated with ondansetron 4 mg (1.0%). </p>
<p><span class="Italics">Other Studies</span></p>
<p>In addition, two serious adverse experiences were reported in <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (PONV) clinical studies in patients taking a higher dose of aprepitant: one case of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and one case of sub-<span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> were reported as serious adverse experiences in a patient receiving aprepitant in a non-CINV/non-PONV study. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8497119c-f7c1-4c11-8dd1-935a96d18161"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postmarketing use of aprepitant. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to the drug.</p>
<p><span class="Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, rarely <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>/<span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_1c8b96ab-24e3-431d-8ec4-5d31e78fed9c"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Aprepitant is a substrate, a weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_807cf647-b0d3-4534-8919-4519f8a90768"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Effect of Aprepitant on the Pharmacokinetics of Other Agents</h2>
<p class="First"><span class="Italics"><span class="Bold">CYP3A4 Substrates:</span></span></p>
<p>Weak inhibition of CYP3A4 by a single 40Â mg dose of aprepitant is not expected to alter the plasma concentrations of concomitant medications that are primarily metabolized through CYP3A4 to a clinically significant degree. However, higher aprepitant doses or repeated dosing at any aprepitant dose may have a clinically significant effect.</p>
<p>As a moderate inhibitor of CYP3A4 at a dose of 125Â mg/80Â mg, aprepitant can increase plasma concentrations of concomitantly administered oral medications that are metabolized through CYP3A4 <span class="Italics">[see <a href="#i4i_contraindications_id_496b9c54-2ac9-4b1e-85a9-e907309d4432">Contraindications (4)</a>]</span>. The use of fosaprepitant may increase CYP3A4 substrate plasma concentrations to a lesser degree than the use of oral aprepitant (125 mg).</p>
<p><span class="Bold"><span class="Italics">5-HT<span class="Sub">3</span> antagonists:</span></span> In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron).</p>
<p><span class="Bold"><span class="Italics">Corticosteroids:</span></span></p>
<p><span class="Italics">Dexamethasone:</span> EMEND, when given as a regimen of 125Â mg with dexamethasone coadministered orally as 20Â mg on DayÂ 1, and EMEND when given as 80Â mg/day with dexamethasone coadministered orally as 8Â mg on DaysÂ 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate, by 2.2-fold on DaysÂ 1 and 5. The oral dexamethasone doses should be reduced by approximately 50% when coadministered with EMEND (125Â mg/80Â mg regimen), to achieve exposures of dexamethasone similar to those obtained when it is given without EMEND. The daily dose of dexamethasone administered in clinical chemotherapy induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> studies with EMEND reflects an approximate 50% reduction of the dose of dexamethasone <span class="Italics">[see <a href="#i4i_section_id_4d51ebb6-20d4-49a7-ab39-ea6c92216e71">Dosage and Administration (2.1)</a>]</span>. A single dose of EMEND (40Â mg) when coadministered with a single oral dose of dexamethasone 20Â mg, increased the AUC of dexamethasone by 1.45-fold. Therefore, no dose adjustment is recommended.</p>
<p><span class="Italics">Methylprednisolone: </span>EMEND, when given as a regimen of 125Â mg on DayÂ 1 and 80Â mg/day on DaysÂ 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on DayÂ 1 and by 2.5-fold on DayÂ 3, when methylprednisolone was coadministered intravenously as 125Â mg on DayÂ 1 and orally as 40Â mg on DaysÂ 2 and 3. The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with EMEND (125Â mg/80Â mg regimen) to achieve exposures of methylprednisolone similar to those obtained when it is given without EMEND. Although the concomitant administration of methylprednisolone with the single 40Â mg dose of aprepitant has not been studied, a single 40Â mg dose of EMEND produces a weak inhibition of CYP3A4 (based on midazolam interaction study) and it is not expected to alter the plasma concentrations of methylprednisolone to a clinically significant degree. Therefore, no dose adjustment is recommended.</p>
<p><span class="Bold"><span class="Italics">Chemotherapeutic agents:</span></span><span class="Italics"> [see <a href="#i4i_warnings_precautions_id_999aab6d-7353-40ae-9e9e-932f286f1d5b">Warnings and Precautions (5.1)</a>]</span></p>
<p><span class="Italics">Docetaxel:</span> In a pharmacokinetic study, EMEND (125Â mg/80Â mg regimen) did not influence the pharmacokinetics of docetaxel.</p>
<p><span class="Italics">Vinorelbine</span>: In a pharmacokinetic study, EMEND (125Â mg/80Â mg regimen) did not influence the pharmacokinetics of vinorelbine to a clinically significant degree. </p>
<p><span class="Bold"><span class="Italics">CYP2C9 Substrates (Warfarin, Tolbutamide):</span></span></p>
<p>Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9. Coadministration of EMEND with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.</p>
<p><span class="Bold"><span class="Italics">Warfarin:</span></span> A single 125-mg dose of EMEND was administered on DayÂ 1 and 80Â mg/day on DaysÂ 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy. Although there was no effect of EMEND on the plasma AUC of R(+) or S(-) warfarin determined on DayÂ 3, there was a 34% decrease in S(-) warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (reported as International Normalized Ratio or INR) 5Â days after completion of dosing with EMEND. In patients on chronic warfarin therapy, the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10Â days, following initiation of the 3-day regimen of EMEND with each chemotherapy cycle, or following administration of a single 40Â mg dose of EMEND for the prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Bold"><span class="Italics">Tolbutamide: </span></span>EMEND, when given as 125Â mg on DayÂ 1 and 80Â mg/day on DaysÂ 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on DayÂ 4, 28% on DayÂ 8, and 15% on DayÂ 15, when a single dose of tolbutamide 500Â mg was administered orally prior to the administration of the 3-day regimen of EMEND and on DaysÂ 4, 8, and 15.</p>
<p>EMEND, when given as a 40-mg single oral dose on DayÂ 1, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 8% on DayÂ 2, 16% on DayÂ 4, 15% on DayÂ 8, and 10% on DayÂ 15, when a single dose of tolbutamide 500Â mg was administered orally prior to the administration of EMEND 40Â mg and on DaysÂ 2, 4, 8, and 15. This effect was not considered clinically important.</p>
<p><span class="Bold"><span class="Italics">Oral contraceptives:</span></span> Aprepitant, when given once daily for 14Â days as a 100-mg capsule with an oral contraceptive containing 35Â mcg of ethinyl estradiol and 1Â mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%. </p>
<p>In another study, a daily dose of an oral contraceptive containing ethinyl estradiol and norethindrone was administered on DaysÂ 1 through 21, and EMEND was given as a 3-day regimen of 125Â mg on DayÂ 8 and 80Â mg/day on DaysÂ 9 and 10 with ondansetron 32Â mg IV on DayÂ 8 and oral dexamethasone given as 12Â mg on DayÂ 8 and 8Â mg/day on DaysÂ 9, 10, and 11. In the study, the AUC of ethinyl estradiol decreased by 19% on DayÂ 10 and there was as much as a 64% decrease in ethinyl estradiol trough concentrations during DaysÂ 9 through 21. While there was no effect of EMEND on the AUC of norethindrone on DayÂ 10, there was as much as a 60% decrease in norethindrone trough concentrations during DaysÂ 9 through 21.</p>
<p>In another study, a daily dose of an oral contraceptive containing ethinyl estradiol and norgestimate (which is converted to norelgestromin) was administered on DaysÂ 1 through 21, and EMEND 40Â mg was given on DayÂ 8. In the study, the AUC of ethinyl estradiol decreased by 4% and 29% on DayÂ 8 and DayÂ 12, respectively, while the AUC of norelgestromin increased by 18% on DayÂ 8 and decreased by 10% on DayÂ 12. In addition, the trough concentrations of ethinyl estradiol and norelgestromin on DaysÂ 8 through 21 were generally lower following coadministration of the oral contraceptive with EMEND 40Â mg on DayÂ 8 compared to the trough levels following administration of the oral contraceptive alone.</p>
<p>The coadministration of EMEND may reduce the efficacy of hormonal contraceptives (these can include birth control pills, skin patches, implants, and certain IUDs) during and for 28Â days after administration of the last dose of EMEND. Alternative or back-up methods of contraception should be used during treatment with EMEND and for 1Â month following the last dose of EMEND.</p>
<p><span class="Bold"><span class="Italics">Midazolam:</span></span> EMEND increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on DayÂ 1 and 3.3-fold on DayÂ 5, when a single oral dose of midazolam 2Â mg was coadministered on DayÂ 1 and DayÂ 5 of a regimen of EMEND 125Â mg on DayÂ 1 and 80Â mg/day on DaysÂ 2 through 5. The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with EMEND (125Â mg/80Â mg). A single dose of EMEND (40Â mg) increased the AUC of midazolam by 1.2-fold on DayÂ 1, when a single oral dose of midazolam 2Â mg was coadministered on DayÂ 1 with EMEND 40Â mg; this effect was not considered clinically important.</p>
<p>In another study with intravenous administration of midazolam, EMEND was given as 125Â mg on DayÂ 1 and 80Â mg/day on DaysÂ 2 and 3, and midazolam 2Â mg IV was given prior to the administration of the 3-day regimen of EMEND and on DaysÂ 4, 8, and 15. EMEND increased the AUC of midazolam by 25% on DayÂ 4 and decreased the AUC of midazolam by 19% on DayÂ 8 relative to the dosing of EMEND on DaysÂ 1 through 3. These effects were not considered clinically important. The AUC of midazolam on DayÂ 15 was similar to that observed at baseline.</p>
<p>An additional study was completed with intravenous administration of midazolam and EMEND. Intravenous midazolam 2Â mg was given 1Â hour after oral administration of a single dose of EMEND 125Â mg. The plasma AUC of midazolam was increased by 1.5-fold. Depending on clinical situations (e.g., elderly patients) and degree of monitoring available, dosage adjustment for intravenous midazolam may be necessary when it is coadministered with EMEND for the chemotherapy induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> indication (125Â mg on DayÂ 1 followed by 80Â mg on DaysÂ 2 and 3).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_37c4ac6d-aabe-486e-902f-9a2c189c57c1"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Effect of Other Agents on the Pharmacokinetics of Aprepitant</h2>
<p class="First">Aprepitant is a substrate for CYP3A4; therefore, coadministration of EMEND with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of aprepitant. Consequently, concomitant administration of EMEND with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution. Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in a 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.</p>
<p>Aprepitant is a substrate for CYP3A4; therefore, coadministration of EMEND with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of EMEND.</p>
<p><span class="Bold"><span class="Italics">Ketoconazole:</span></span> When a single 125-mg dose of EMEND was administered on DayÂ 5 of a 10-day regimen of 400Â mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold. Concomitant administration of EMEND with strong CYP3A4 inhibitors should be approached cautiously. </p>
<p><span class="Bold"><span class="Italics">Rifampin:</span></span> When a single 375-mg dose of EMEND was administered on DayÂ 9 of a 14-day regimen of 600Â mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold. </p>
<p>Coadministration of EMEND with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of EMEND.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3b522f87-10bd-4ed1-9977-80e046330aae"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Additional Interactions</h2>
<p class="First">EMEND is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of EMEND with digoxin in a clinical drug interaction study.</p>
<p><span class="Bold"><span class="Italics">Diltiazem:</span></span> In patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, administration of aprepitant once daily, as a tablet formulation comparable to 230Â mg of the capsule formulation, with diltiazem 120Â mg 3Â times daily for 5Â days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC. These pharmacokinetic effects did not result in clinically meaningful changes in ECG, heart rate or blood pressure beyond those changes induced by diltiazem alone.</p>
<p><span class="Bold"><span class="Italics">Paroxetine:</span></span> Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85Â mg or 170Â mg of the capsule formulation, with paroxetine 20Â mg once daily, resulted in a decrease in AUC by approximately 25% and C<span class="Sub">max</span> by approximately 20% of both aprepitant and paroxetine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_d52d13c9-7f05-475e-883b-f0f2adfed5b9"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_be8a0d94-d5f6-4e1d-a23c-1e96c1677554"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic effects</span></p>
<p>Pregnancy Category B: Reproduction studies have been performed in rats at oral doses up to 1000 mg/kg twice daily (plasma AUC<span class="Sub">0â€‘24hr</span> of 31.3 mcgâ€¢hr/mL, about 1.6 times the human exposure at the recommended dose) and in rabbits at oral doses up to 25 mg/kg/day (plasma AUC<span class="Sub">0â€‘24hr</span> of 26.9 mcgâ€¢hr/mL, about 1.4 times the human exposure at the recommended dose) and have revealed no evidence of impaired fertility or harm to the fetus due to aprepitant. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_19de7ff1-6f95-4dee-a560-8d082a6322e3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Aprepitant is excreted in the milk of rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for possible serious adverse reactions in nursing infants from aprepitant and because of the potential for tumorigenicity shown for aprepitant in rodent carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_533fd0c2-82df-4614-b199-a8c9f9068e30"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of EMEND in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_9b64471a-c845-4c6c-861b-ff706a361bfb"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In 2 well-controlled chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> clinical studies, of the total number of patients (N=544) treated with EMEND, 31% were 65 and over, while 5% were 75 and over. In well-controlled <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> clinical studies, of the total number of patients (N=1120) treated with EMEND, 7% were 65 and over, while 2% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Greater sensitivity of some older individuals cannot be ruled out. Dosage adjustment in the elderly is not necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_316261f8-7bf8-4aa7-bb00-5dc0639dcf53"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No specific information is available on the treatment of overdosage.</p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> were reported in one patient who ingested 1440 mg of aprepitant.</p>
<p>In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, EMEND should be discontinued and general supportive treatment and monitoring should be provided. Because of the antiemetic activity of aprepitant, drug-induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> may not be effective.</p>
<p>Aprepitant cannot be removed by hemodialysis. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_23b689ed-4ab2-4f37-815e-d94b11809165"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">EMEND (aprepitant) is a substance P/neurokinin 1 (NK<span class="Sub">1</span>) receptor antagonist, chemically described as 5-[[(2<span class="Italics">R</span>,3<span class="Italics">S</span>)-2-[(1<span class="Italics">R</span>)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3<span class="Italics">H</span>-1,2,4-triazol-3-one. </p>
<p>Its empirical formula is C<span class="Sub">23</span>H<span class="Sub">21</span>F<span class="Sub">7</span>N<span class="Sub">4</span>O<span class="Sub">3</span>, and its structural formula is:</p>
<div class="Figure"><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec44482e-6194-4829-a3f7-ebe8d48a41a5&amp;name=ec44482e-6194-4829-a3f7-ebe8d48a41a5-01.jpg"></div>
<p>Aprepitant is a white to off-white crystalline solid, with a molecular weight of 534.43. It is practically insoluble in water. Aprepitant is sparingly soluble in ethanol and isopropyl acetate and slightly soluble in acetonitrile.</p>
<p>Each capsule of EMEND for oral administration contains either 40 mg, 80 mg, or 125 mg of aprepitant and the following inactive ingredients: sucrose, microcrystalline cellulose, hydroxypropyl cellulose and sodium lauryl sulfate. The capsule shell excipients are gelatin, titanium dioxide, and may contain sodium lauryl sulfate and silicon dioxide. The 40â€‘mg capsule shell also contains yellow ferric oxide, and the 125â€‘mg capsule also contains red ferric oxide and yellow ferric oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f6a3817a-277a-473c-9c5b-ff025050a9ff"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_5b3cf8b7-f435-4a1a-866f-80c367b2774e"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK<span class="Sub">1</span>) receptors. Aprepitant has little or no affinity for serotonin (5-HT<span class="Sub">3</span>), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (CINV) and <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (PONV).</p>
<p>Aprepitant has been shown in animal models to inhibit <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK<span class="Sub">1</span> receptors. Animal and human studies show that aprepitant augments the antiemetic activity of the 5-HT<span class="Sub">3</span>-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_c60b9bf1-47bc-4218-a433-7dc6cc14ed82"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Italics">NK<span class="Sub">1</span> Receptor Occupancy</span></p>
<p>In two single-blind, multiple-dose, randomized, and placebo control studies, healthy young men received oral aprepitant doses of 10 mg (N=2), 30 mg (N=3), 100 mg (N=3) or 300 mg (N=5) once daily for 14 days with 2 or 3 subjects on placebo. Both plasma aprepitant concentration and NK<span class="Sub">1</span> receptor occupancy in the corpus striatum by positron emission tomography were evaluated, at predose and 24 hours after the last dose. At aprepitant plasma concentrations of ~10 ng/mL and ~100 ng/mL, the NK<span class="Sub">1</span> receptor occupancies were ~50% and ~90%, respectively. The oral aprepitant regimen for CINV produces mean trough plasma aprepitant concentrations &gt;500 ng/mL, which would be expected to, based on the fitted curve with the Hill equation, result in &gt;95% brain NK<span class="Sub">1</span> receptor occupancy. However, the receptor occupancy for either CINV or PONV dosing regimen has not been determined. In addition, the relationship between NK<span class="Sub">1</span> receptor occupancy and the clinical efficacy of aprepitant has not been established.</p>
<p><span class="Italics">Cardiac Electrophysiology</span></p>
<p>In a randomized, double-blind,Â positive-controlled, thorough QTcÂ study, a single 200-mg dose of fosaprepitant had no effect on the QTc interval. QT prolongation with the oral dosing regimens for CINV and PONV are not expected. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_23b615f3-edc9-4948-8d83-3cc71cd09989"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption</span></p>
<p>Following oral administration of a single 40 mg dose of EMEND in the fasted state, mean area under the plasma concentration-time curve (AUC<span class="Sub">0â€‘âˆž</span>) was 7.8 mcgâ€¢hr/mL and mean peak plasma concentration (C<span class="Sub">max</span>) was 0.7 mcg/mL, occurring at approximately 3 hours postdose (T<span class="Sub">max</span>). The absolute bioavailability at the 40â€‘mg dose has not been determined.</p>
<p>Following oral administration of a single 125-mg dose of EMEND on Day 1 and 80 mg once daily on Days 2 and 3, the AUC<span class="Sub">0-24hr</span> was approximately 19.6 mcgâ€¢hr/mL and 21.2 mcgâ€¢hr/mL on Day 1 and Day 3, respectively. The C<span class="Sub">max</span> of 1.6 mcg/mL and 1.4 mcg/mL were reached in approximately 4 hours (T<span class="Sub">max</span>) on Day 1 and Day 3, respectively. At the dose range of 80-125 mg, the mean absolute oral bioavailability of aprepitant is approximately 60 to 65%. Oral administration of the capsule with a standard high-fat breakfast had no clinically meaningful effect on the bioavailability of aprepitant.</p>
<p>The pharmacokinetics of aprepitant are non-linear across the clinical dose range. In healthy young adults, the increase in AUC<span class="Sub">0â€‘âˆž</span> was 26% greater than dose proportional between 80â€‘mg and 125â€‘mg single doses administered in the fed state. </p>
<p><span class="Italics">Distribution</span></p>
<p>Aprepitant is greater than 95% bound to plasma proteins. The mean apparent volume of distribution at steady state (Vd<span class="Sub">ss</span>) is approximately 70Â L in humans. </p>
<p>Aprepitant crosses the placenta in rats and rabbits and crosses the blood brain barrier in humans <span class="Italics">[see <a href="#i4i_mechanism_action_id_5b3cf8b7-f435-4a1a-866f-80c367b2774e">Clinical Pharmacology (12.1)</a>]</span>.</p>
<p><span class="Italics">Metabolism</span></p>
<p>Aprepitant undergoes extensive metabolism. <span class="Italics">In vitro</span> studies using human liver microsomes indicate that aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Metabolism is largely via oxidation at the morpholine ring and its side chains. No metabolism by CYP2D6, CYP2C9, or CYP2E1 was detected. In healthy young adults, aprepitant accounts for approximately 24% of the radioactivity in plasma over 72 hours following a single oral 300-mg dose of [<span class="Sup">14</span>C]-aprepitant, indicating a substantial presence of metabolites in the plasma. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma.</p>
<p><span class="Italics">Excretion</span></p>
<p>Following administration of a single IV 100-mg dose of [<span class="Sup">14</span>C]-aprepitant prodrug to healthy subjects, 57% of the radioactivity was recovered in urine and 45% in feces. A study was not conducted with radiolabeled capsule formulation. The results after oral administration may differ.</p>
<p>Aprepitant is eliminated primarily by metabolism; aprepitant is not renally excreted. The apparent plasma clearance of aprepitant ranged from approximately 62 to 90 mL/min. The apparent terminal half-life ranged from approximately 9 to 13 hours.</p>
<p><span class="Italics">Special Populations</span></p>
<p><span class="Italics">Gender</span></p>
<p>Following oral administration of a single 125-mg dose of EMEND, no difference in AUC<span class="Sub">0â€‘24hr</span> was observed between males and females. The C<span class="Sub">max</span> for aprepitant is 16% higher in females as compared with males. The half-life of aprepitant is 25% lower in females as compared with males and T<span class="Sub">max</span> occurs at approximately the same time. These differences are not considered clinically meaningful. No dosage adjustment for EMEND is necessary based on gender.</p>
<p><span class="Italics">Geriatric</span></p>
<p>Following oral administration of a single 125-mg dose of EMEND on Day 1 and 80 mg once daily on Days 2 through 5, the AUC<span class="Sub">0â€‘24hr</span> of aprepitant was 21% higher on Day 1 and 36% higher on Day 5 in elderly (â‰¥65 years) relative to younger adults. The C<span class="Sub">max </span>was 10% higher on Day 1 and 24% higher on Day 5 in elderly relative to younger adults. These differences are not considered clinically meaningful. No dosage adjustment for EMEND is necessary in elderly patients.</p>
<p><span class="Italics">Pediatric</span></p>
<p>EMEND has not been evaluated in patients below 18 years of age.</p>
<p><span class="Italics">Race</span></p>
<p>Following oral administration of a single 125-mg dose of EMEND, the AUC<span class="Sub">0-24hr</span> is approximately 25% and 29% higher in Hispanics as compared with Whites and Blacks, respectively. The C<span class="Sub">max</span> is 22% and 31% higher in Hispanics as compared with Whites and Blacks, respectively. These differences are not considered clinically meaningful. There was no difference in AUC<span class="Sub">0-24hr</span> or C<span class="Sub">max</span> between Whites and Blacks. No dosage adjustment for EMEND is necessary based on race.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></p>
<p>Following administration of a single 125â€‘mg dose of EMEND on Day 1 and 80 mg once daily on Days 2 and 3 to patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 5 to 6), the AUC<span class="Sub">0-24hr </span>of aprepitant was 11% lower on Day 1 and 36% lower on Day 3, as compared with healthy subjects given the same regimen. In patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 7 to 9), the AUC<span class="Sub">0-24hr</span> of aprepitant was 10% higher on Day 1 and 18% higher on Day 3, as compared with healthy subjects given the same regimen. These differences in AUC<span class="Sub">0â€‘24hr</span> are not considered clinically meaningful; therefore, no dosage adjustment for EMEND is necessary in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>There are no clinical or pharmacokinetic data in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score &gt;9) <span class="Italics">[see <a href="#i4i_section_id_30ea6ad6-04ae-4309-a8a1-625600d1f919">Warnings and Precautions (5.4)</a>]</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></p>
<p>A single 240-mg dose of EMEND was administered to patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl&lt;30Â mL/min) and to patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) requiring hemodialysis.</p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the AUC<span class="Sub">0-âˆž</span> of total aprepitant (unbound and protein bound) decreased by 21% and C<span class="Sub">max</span> decreased by 32%, relative to healthy subjects. In patients with ESRD undergoing hemodialysis, the AUC<span class="Sub">0â€‘âˆž</span> of total aprepitant decreased by 42% and C<span class="Sub">max</span> decreased by 32%. Due to modest decreases in protein binding of aprepitant in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, the AUC of pharmacologically active unbound drug was not significantly affected in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with healthy subjects. Hemodialysis conducted 4 or 48 hours after dosing had no significant effect on the pharmacokinetics of aprepitant; less than 0.2% of the dose was recovered in the dialysate.</p>
<p>No dosage adjustment for EMEND is necessary for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or for patients with ESRD undergoing hemodialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_626383c0-0b57-4aa5-9ee1-a0c82a45aedc"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_1ec5b998-6b01-404a-8179-af97aab772d0"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies were conducted in Sprague-Dawley rats and in CD-1 mice for 2 years. In the rat carcinogenicity studies, animals were treated with oral doses ranging from 0.05 to 1000 mg/kg twice daily. The highest dose produced a systemic exposure to aprepitant (plasma AUC<span class="Sub">0â€‘24hr</span>) of 0.7 to 1.6 times the human exposure (AUC<span class="Sub">0â€‘24hr</span> = 19.6 mcgâ€¢hr/mL) at the recommended dose of 125 mg/day. Treatment with aprepitant at doses of 5 to 1000 mg/kg twice daily caused an increase in the incidences of thyroid follicular cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas in male rats. In female rats, it produced <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> at 5 to 1000 mg/kg twice daily and hepatocellular carcinomas and thyroid follicular cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> at 125 to 1000 mg/kg twice daily. In the mouse carcinogenicity studies, the animals were treated with oral doses ranging from 2.5 to 2000 mg/kg/day. The highest dose produced a systemic exposure of about 2.8 to 3.6 times the human exposure at the recommended dose. Treatment with aprepitant produced skin <span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcomas</span> at 125 and 500 mg/kg/day doses in male mice. </p>
<p>Aprepitant was not genotoxic in the Ames test, the human lymphoblastoid cell (TK6) mutagenesis test, the rat hepatocyte DNA strand break test, the Chinese hamster ovary (CHO) cell chromosome aberration test and the mouse micronucleus test. </p>
<p>Aprepitant did not affect the fertility or general reproductive performance of male or female rats at doses up to the maximum feasible dose of 1000 mg/kg twice daily (providing exposure in male rats lower than the exposure at the recommended human dose and exposure in female rats at about 1.6 times the human exposure).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_d375b0c1-113c-46f6-b858-9fc667200984"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_74893d60-9613-4f4e-9c37-53ab4a1f5c7b"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Prevention of Chemotherapy Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (CINV)</h2>
<p class="First">Oral administration of EMEND in combination with ondansetron and dexamethasone (aprepitant regimen) has been shown to prevent acute and delayed <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with highly emetogenic chemotherapy including high-dose cisplatin, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with moderately emetogenic chemotherapy.</p>
<p><span class="Underline"><span class="Italics">Highly Emetogenic Chemotherapy (HEC)</span></span></p>
<p>In 2 multicenter, randomized, parallel, double-blind, controlled clinical studies, the aprepitant regimen (see Table 6) was compared with standard therapy in patients receiving a chemotherapy regimen that included cisplatin &gt;50 mg/m<span class="Sup">2</span> (mean cisplatin dose = 80.2 mg/m<span class="Sup">2</span>). Of the 550 patients who were randomized to receive the aprepitant regimen, 42% were women, 58% men, 59% White, 3% Asian, 5% Black, 12% Hispanic American, and 21% Multi-Racial. The aprepitant-treated patients in these clinical studies ranged from 14 to 84 years of age, with a mean age of 56 years. 170 patients were 65 years or older, with 29 patients being 75 years or older.</p>
<p>Patients (N = 1105) were randomized to either the aprepitant regimen (NÂ =Â 550) or standard therapy (NÂ =Â 555). The treatment regimens are defined in Table 5.</p>
<a name="id_4a15cec3-72b2-4d4a-8fac-c861ab432800"></a><table width="730.000">
<caption><span>Table 5: Treatment Regimens in Highly Emetogenic Chemotherapy Trials</span></caption>
<col width="21.8%">
<col width="30.8%">
<col width="47.4%">
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" valign="top">Aprepitant placebo and dexamethasone placebo were used to maintain blinding.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Treatment Regimen</td>
<td class="Botrule" align="center" valign="top">Day 1</td>
<td class="Botrule" align="center" valign="top">Days 2 to 4</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Aprepitant</td>
<td class="Botrule" align="left" valign="top">Aprepitant 125 mg PO <br><br>Dexamethasone 12 mg PO <br>Ondansetron 32 mg I.V. </td>
<td class="Botrule" align="left" valign="top">Aprepitant 80 mg PO Daily (Days 2 and 3 only)<br> Dexamethasone 8 mg PO Daily (morning)</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Standard Therapy</td>
<td align="left" valign="top">Dexamethasone 20 mg PO <br><br>Ondansetron 32 mg I.V. </td>
<td align="left" valign="top">Dexamethasone 8 mg PO Daily (morning) <br><br>Dexamethasone 8 mg PO Daily (evening)</td>
</tr>
</tbody>
</table>
<p>During these studies 95% of the patients in the aprepitant group received a concomitant chemotherapeutic agent in addition to protocol-mandated cisplatin. The most common chemotherapeutic agents and the number of aprepitant patients exposed follows: etoposide (106), fluorouracil (100), gemcitabine (89), vinorelbine (82), paclitaxel (52), cyclophosphamide (50), doxorubicin (38), docetaxel (11).</p>
<p>The antiemetic activity of EMEND was evaluated during the acute phase (0 to 24 hours post-cisplatin treatment), the delayed phase (25 to 120 hours post-cisplatin treatment) and overall (0 to 120 hours post-cisplatin treatment) in Cycle 1. Efficacy was based on evaluation of the following endpoints: </p>
<p>Primary endpoint: </p>
<ul><li>complete response (defined as no emetic episodes and no use of rescue therapy)</li></ul>
<p>Other prespecified endpoints: </p>
<ul>
<li>complete protection (defined as no emetic episodes, no use of rescue therapy, and a maximum <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> visual analogue scale [VAS] score &lt;25 mm on a 0 to 100 mm scale)</li>
<li>no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (defined as no emetic episodes regardless of use of rescue therapy) </li>
<li>no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (maximum VAS &lt;5 mm on a 0 to 100 mm scale) </li>
<li>no significant <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (maximum VAS &lt;25 mm on a 0 to 100 mm scale)</li>
</ul>
<p>A summary of the key study results from each individual study analysis is shown in Table 6 and in Table 7.</p>
<a name="id_c09790fa-72ba-4383-85b7-d6e0ff27cd9a"></a><table width="609.000">
<caption><span>Table 6: Percent of Patients Receiving Highly Emetogenic Chemotherapy Responding by Treatment Group and Phase for Study 1 â€” Cycle 1</span></caption>
<col width="37.9%">
<col width="20.7%">
<col width="22.5%">
<col width="18.9%">
<thead><tr class="Botrule First Last">
<td class="Lrule" align="left" valign="top">ENDPOINTS</td>
<td align="center" valign="top">Aprepitant<br>Regimen<br>(N = 260)<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a><br>%</td>
<td align="center" valign="top">Standard <br>Therapy <br>(N = 261)<a href="#footnote-8" class="Sup">*</a><br>%</td>
<td class="Botrule" align="center" valign="top">p-Value</td>
</tr></thead>
<tfoot>
<tr class="Last"><td align="left" colspan="4" valign="top">Visual analogue scale (VAS) score range: 0 mm = no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; 100 mm = <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> as bad as it could be.</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>N: Number of patients (older than 18 years of age) who received cisplatin, study drug, and had at least one post-treatment efficacy evaluation.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">â€ </a></dt>
<dd>Overall: 0 to 120 hours post-cisplatin treatment.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">â€¡</a></dt>
<dd>Acute phase: 0 to 24 hours post-cisplatin treatment.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">Â§</a></dt>
<dd>Delayed phase: 25 to 120 hours post-cisplatin treatment. </dd>
<dt><a name="footnote-12" href="#footnote-reference-12">Â¶</a></dt>
<dd>Not statistically significant when adjusted for multiple comparisons.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">#</a></dt>
<dd>Not statistically significant.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First Toprule"><td class="Botrule" align="left" colspan="4" valign="top">PRIMARY ENDPOINT</td></tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">Complete Response </td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Overall<a name="footnote-reference-9" href="#footnote-9" class="Sup">â€ </a>
</td>
<td class="Botrule" align="center" valign="top">73</td>
<td class="Botrule" align="center" valign="top">52</td>
<td class="Botrule" align="center" valign="top">&lt;0.001</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">OTHER PRESPECIFIED ENDPOINTS</td></tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">Complete Response</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Acute phase<a name="footnote-reference-10" href="#footnote-10" class="Sup">â€¡</a><br>Â Â Â Â Delayed phase<a name="footnote-reference-11" href="#footnote-11" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="top">89<br>75</td>
<td class="Botrule" align="center" valign="top">78<br>56 </td>
<td class="Botrule" align="center" valign="top">&lt;0.001<br>&lt;0.001</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">Complete Protection</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Overall<br>Â Â Â Â Acute phase <br>Â Â Â Â Delayed phase </td>
<td class="Botrule" align="center" valign="top">63<br>85<br>66</td>
<td class="Botrule" align="center" valign="top">49<br>75<br>52</td>
<td class="Botrule" align="center" valign="top">0.001<br>NS<a name="footnote-reference-12" href="#footnote-12" class="Sup">Â¶</a><br>&lt;0.001</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Overall <br>Â Â Â Â Acute phase<br>Â Â Â Â Delayed phase</td>
<td class="Botrule" align="center" valign="top">78<br>90<br>81</td>
<td class="Botrule" align="center" valign="top">55<br>79<br>59</td>
<td class="Botrule" align="center" valign="top">&lt;0.001<br>0.001<br>&lt;0.001</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Overall<br>Â Â Â Â Delayed phase</td>
<td class="Botrule" align="center" valign="top">48<br>51</td>
<td class="Botrule" align="center" valign="top">44<br>48</td>
<td class="Botrule" align="center" valign="top">NS<a name="footnote-reference-13" href="#footnote-13" class="Sup">#</a><br>NS<a href="#footnote-13" class="Sup">#</a>
</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">No Significant <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td></tr>
<tr class="Last">
<td align="left" valign="top">Â Â Â Â Overall<br>Â Â Â Â Delayed phase </td>
<td align="center" valign="top">73<br>75</td>
<td align="center" valign="top">66<br>69</td>
<td align="center" valign="top">NS<a href="#footnote-13" class="Sup">#</a><br>NS<a href="#footnote-13" class="Sup">#</a>
</td>
</tr>
</tbody>
</table>
<a name="id_a996da40-9cc1-46fc-bf4c-0934d9b0c22c"></a><table width="599.000">
<caption><span>Table 7: Percent of Patients Receiving Highly Emetogenic Chemotherapy Responding by Treatment Group and Phase for Study 2 â€” Cycle 1</span></caption>
<col width="40.4%">
<col width="18.4%">
<col width="20.2%">
<col width="21.0%">
<tfoot>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="4" valign="top">Visual analogue scale (VAS) score range: 0 mm = no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; 100 mm = <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> as bad as it could be.</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>N: Number of patients (older than 18 years of age) who received cisplatin, study drug, and had at least one post-treatment efficacy evaluation.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">â€ </a></dt>
<dd>Overall: 0 to 120 hours post-cisplatin treatment.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">â€¡</a></dt>
<dd>Acute phase: 0 to 24 hours post-cisplatin treatment.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">Â§</a></dt>
<dd>Delayed phase: 25 to 120 hours post-cisplatin treatment.</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">Â¶</a></dt>
<dd>Not statistically significant when adjusted for multiple comparisons.</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">#</a></dt>
<dd>Not statistically significant.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">ENDPOINTS</td>
<td class="Botrule" align="center" valign="top">Aprepitant <br>Regimen <br>(N = 261)<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a><br>%</td>
<td class="Botrule" align="center" valign="top">Standard<br>Therapy<br>(N = 263)<a href="#footnote-14" class="Sup">*</a><br>%</td>
<td class="Botrule" align="center" valign="top">p-Value</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">PRIMARY ENDPOINT</td></tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">Complete Response </td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Overall<a name="footnote-reference-15" href="#footnote-15" class="Sup">â€ </a>
</td>
<td class="Botrule" align="center" valign="top">63</td>
<td class="Botrule" align="center" valign="top">43</td>
<td class="Botrule" align="center" valign="top">&lt;0.001</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">OTHER PRESPECIFIED ENDPOINTS</td></tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">Complete Response</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Acute phase<a name="footnote-reference-16" href="#footnote-16" class="Sup">â€¡</a><br>Â Â Â Â Delayed phase<a name="footnote-reference-17" href="#footnote-17" class="Sup">Â§</a>
</td>
<td class="Botrule" align="center" valign="top">83<br>68</td>
<td class="Botrule" align="center" valign="top">68<br>47</td>
<td class="Botrule" align="center" valign="top">&lt;0.001<br>&lt;0.001</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">Complete Protection</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Overall<br>Â Â Â Â Acute phase<br>Â Â Â Â Delayed phase </td>
<td class="Botrule" align="center" valign="top">56<br>80<br>61</td>
<td class="Botrule" align="center" valign="top">41<br>65<br>44</td>
<td class="Botrule" align="center" valign="top">&lt;0.001<br>&lt;0.001<br>&lt;0.001</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Overall<br>Â Â Â Â Acute phase<br>Â Â Â Â Delayed phase</td>
<td class="Botrule" align="center" valign="top">66<br>84<br>72</td>
<td class="Botrule" align="center" valign="top">44<br>69<br>48</td>
<td class="Botrule" align="center" valign="top">&lt;0.001<br>&lt;0.001<br>&lt;0.001</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Overall<br>Â Â Â Â Delayed phase</td>
<td class="Botrule" align="center" valign="top">49<br>53</td>
<td class="Botrule" align="center" valign="top">39<br>40</td>
<td class="Botrule" align="center" valign="top">NS<a name="footnote-reference-18" href="#footnote-18" class="Sup">Â¶</a><br>NS<a href="#footnote-18" class="Sup">Â¶</a>
</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">No Significant <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td></tr>
<tr class="Last">
<td align="left" valign="top">Â Â Â Â Overall<br>Â Â Â Â Delayed phase </td>
<td align="center" valign="top">71<br>73</td>
<td align="center" valign="top">64<br>65</td>
<td align="center" valign="top">NS<a name="footnote-reference-19" href="#footnote-19" class="Sup">#</a><br>NS<a href="#footnote-19" class="Sup">#</a>
</td>
</tr>
</tbody>
</table>
<p>In both studies, a statistically significantly higher proportion of patients receiving the aprepitant regimen in Cycle 1 had a complete response in the overall phase (primary endpoint), compared with patients receiving standard therapy. A statistically significant difference in complete response in favor of the aprepitant regimen was also observed when the acute phase and the delayed phase were analyzed separately.</p>
<p>In both studies, the estimated time to first <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> after initiation of cisplatin treatment was longer with the aprepitant regimen, and the incidence of first <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> was reduced in the aprepitant regimen group compared with standard therapy group as depicted in the Kaplan-Meier curves in Figure 1.</p>
<div class="Figure">
<img alt="image of figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec44482e-6194-4829-a3f7-ebe8d48a41a5&amp;name=ec44482e-6194-4829-a3f7-ebe8d48a41a5-02.jpg"><p class="MultiMediaCaption">Figure 1: Percent of Patients Receiving Highly Emetogenic Chemotherapy Who Remain <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> Free Over Time â€” CycleÂ 1</p>
</div>
<p><span class="Italics">Patient-Reported Outcomes:</span> The impact of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> on patientsâ€™ daily lives was assessed in Cycle 1 of both Phase III studies using the Functional Living Indexâ€“<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> (FLIE), a validated <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>- and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>-specific patient-reported outcome measure. Minimal or no impact of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> on patientsâ€™ daily lives is defined as a FLIE total score &gt;108. In each of the 2 studies, a higher proportion of patients receiving the aprepitant regimen reported minimal or no impact of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> on daily life (Study 1: 74% versus 64%; Study 2: 75% versus 64%).</p>
<p><span class="Italics">Multiple-Cycle Extension:</span> In the same 2 clinical studies, patients continued into the Multiple-Cycle extension for up to 5 additional cycles of chemotherapy. The proportion of patients with no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and no significant <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> by treatment group at each cycle is depicted in Figure 2. Antiemetic effectiveness for the patients receiving the aprepitant regimen is maintained throughout repeat cycles for those patients continuing in each of the multiple cycles.</p>
<div class="Figure">
<img alt="image of figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec44482e-6194-4829-a3f7-ebe8d48a41a5&amp;name=ec44482e-6194-4829-a3f7-ebe8d48a41a5-03.jpg"><p class="MultiMediaCaption">Figure 2: Proportion of Patients Receiving Highly Emetogenic Chemotherapy with No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> and No Significant <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> by Treatment Group and Cycle</p>
</div>
<p><span class="Underline"><span class="Italics">Moderately Emetogenic Chemotherapy (MEC)</span></span></p>
<p>In a multicenter, randomized, double-blind, parallel-group, clinical study in breast cancer patients, the aprepitant regimen (see Table 9) was compared with a standard of care therapy in patients receiving a moderately emetogenic chemotherapy regimen that included cyclophosphamide 750-1500Â mg/m<span class="Sup">2</span>; or cyclophosphamide 500-1500Â mg/m<span class="Sup">2</span> and doxorubicin (â‰¤60Â mg/m<span class="Sup">2</span>) or epirubicin (â‰¤100Â mg/m<span class="Sup">2</span>). </p>
<p>In this study, the most common combinations were cyclophosphamide + doxorubicin (60.6%); and cyclophosphamide + epirubicin + fluorouracil (21.6%). </p>
<p>Of the 438 patients who were randomized to receive the aprepitant regimen, 99.5% were women. Of these, approximately 80% were White, 8% Black, 8% Asian, 4% Hispanic, and &lt;1% Other. The aprepitant-treated patients in this clinical study ranged from 25 to 78 years of age, with a mean age of 53 years; 70 patients were 65 years or older, with 12 patients being over 74 years. </p>
<p>Patients (N = 866) were randomized to either the aprepitant regimen (N = 438) or standard therapy (N = 428). The treatment regimens are defined in Table 8.</p>
<a name="id_73e2b7b8-33a1-4ec9-8b3f-e31e7d6335f8"></a><table width="643.000">
<caption><span>Table 8: Treatment Regimens in Moderately Emetogenic Chemotherapy Trials</span></caption>
<col width="24.7%">
<col width="41.1%">
<col width="34.2%">
<tfoot>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" valign="top">Aprepitant placebo and dexamethasone placebo were used to maintain blinding.</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>1 hour prior to chemotherapy.</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">â€ </a></dt>
<dd>30 minutes prior to chemotherapy.</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">â€¡</a></dt>
<dd>30 to 60 minutes prior to chemotherapy and 8 hours after first ondansetron dose.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Treatment Regimen</td>
<td class="Botrule" align="center" valign="top">Day 1</td>
<td class="Botrule" align="center" valign="top">Days 2 to 3</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Aprepitant</td>
<td class="Botrule" align="left" valign="top">Aprepitant 125 mg PO<a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a><br>Dexamethasone 12 mg PO<a name="footnote-reference-21" href="#footnote-21" class="Sup">â€ </a><br>Ondansetron 8 mg PO x 2 doses<a name="footnote-reference-22" href="#footnote-22" class="Sup">â€¡</a>
</td>
<td class="Botrule" align="left" valign="top">Aprepitant 80 mg PO Daily</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Standard Therapy</td>
<td align="left" valign="top">Dexamethasone 20 mg PO <br>Ondansetron 8 mg PO x 2 doses</td>
<td align="left" valign="top">Ondansetron 8 mg PO Daily (every 12 hours)</td>
</tr>
</tbody>
</table>
<p>The antiemetic activity of EMEND was evaluated based on the following endpoints:</p>
<p>Primary endpoint:</p>
<p>Complete response (defined as no emetic episodes and no use of rescue therapy) in the overall phase (0 to 120 hours post-chemotherapy)</p>
<p> Other prespecified endpoints:</p>
<ul>
<li>no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (defined as no emetic episodes regardless of use of rescue therapy)</li>
<li>no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (maximum VAS &lt;5 mm on a 0 to 100 mm scale)</li>
<li>no significant <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (maximum VAS &lt;25 mm on a 0 to 100 mm scale)</li>
<li>complete protection (defined as no emetic episodes, no use of rescue therapy, and a maximum <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> visual analogue scale [VAS] score &lt;25 mm on a 0 to 100 mm scale)</li>
<li>complete response during the acute and delayed phases.</li>
</ul>
<p>A summary of the key results from this study is shown in Table 9.</p>
<a name="id_8e04613f-cd0b-42dd-aa8e-4731f7086388"></a><table width="615.000">
<caption><span>Table 9: Percent of Patients Receiving Moderately Emetogenic Chemotherapy Responding by Treatment Group and Phase â€” Cycle 1</span></caption>
<col width="37.6%">
<col width="23.3%">
<col width="20.5%">
<col width="18.7%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="top">ENDPOINTS</td>
<td class="Botrule" align="center" valign="top">Aprepitant<br>Regimen<br>(N = 433)<a name="footnote-reference-23" href="#footnote-23" class="Sup">*</a><br>%</td>
<td class="Botrule" align="center" valign="top">Standard <br>Therapy <br>(N = 424)<a href="#footnote-23" class="Sup">*</a><br>%</td>
<td class="Botrule" align="center" valign="top">p-Value</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-23" href="#footnote-reference-23">*</a></dt>
<dd>N: Number of patients included in the primary analysis of complete response.</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">â€ </a></dt>
<dd>Overall: 0 to 120 hours post-chemotherapy treatment.</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">â€¡</a></dt>
<dd>NS when adjusted for prespecified multiple comparisons rule; unadjusted p-value &lt;0.001.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule" align="left" colspan="4" valign="top">PRIMARY ENDPOINT<a name="footnote-reference-24" href="#footnote-24" class="Sup">â€ </a>
</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â Complete Response</td>
<td class="Botrule" align="center" valign="top">51</td>
<td class="Botrule" align="center" valign="top">42</td>
<td class="Botrule" align="center" valign="top">0.015</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">OTHER PRESPECIFIED ENDPOINTS<a href="#footnote-24" class="Sup">â€ </a>
</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â No EmesisÂ  </td>
<td class="Botrule" align="center" valign="top">76</td>
<td class="Botrule" align="center" valign="top">59</td>
<td class="Botrule" align="center" valign="top">NS<a name="footnote-reference-25" href="#footnote-25" class="Sup">â€¡</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td class="Botrule" align="center" valign="top">33</td>
<td class="Botrule" align="center" valign="top">33</td>
<td class="Botrule" align="center" valign="top">NS</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â No Significant NauseaÂ </td>
<td class="Botrule" align="center" valign="top">61</td>
<td class="Botrule" align="center" valign="top">56</td>
<td class="Botrule" align="center" valign="top">NS</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Â Â Â Â No Rescue TherapyÂ Â </td>
<td class="Botrule" align="center" valign="top">59</td>
<td class="Botrule" align="center" valign="top">56</td>
<td class="Botrule" align="center" valign="top">NS</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Â Â Â Â Complete Protection </td>
<td class="Botrule" align="center" valign="top">43</td>
<td class="Botrule" align="center" valign="top">37</td>
<td class="Botrule" align="center" valign="top">NS</td>
</tr>
</tbody>
</table>
<p>In this study, a statistically significantly (p=0.015) higher proportion of patients receiving the aprepitant regimen (51%) in Cycle 1 had a complete response (primary endpoint) during the overall phase compared with patients receiving standard therapy (42%). The difference between treatment groups was primarily driven by the â€œNo <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> Endpointâ€?, a principal component of this composite primary endpoint. In addition, a higher proportion of patients receiving the aprepitant regimen in Cycle 1 had a complete response during the acute (0-24 hours) and delayed (25-120 hours) phases compared with patients receiving standard therapy; however, the treatment group differences failed to reach statistical significance, after multiplicity adjustments. </p>
<p><span class="Italics">Patient-Reported Outcomes:</span> In a phase III study in patients receiving moderately emetogenic chemotherapy, the impact of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> on patientsâ€™ daily lives was assessed in Cycle 1 using the FLIE. A higher proportion of patients receiving the aprepitant regimen reported minimal or no impact on daily life (64% versus 56%). This difference between treatment groups was primarily driven by the â€œNo <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Domainâ€? of this composite endpoint. </p>
<p><span class="Italics">Multiple-Cycle Extension:</span> Patients receiving moderately emetogenic chemotherapy were permitted to continue into the Multiple-Cycle extension of the study for up to 3 additional cycles of chemotherapy. Antiemetic effect for patients receiving the aprepitant regimen is maintained during all cycles.</p>
<p><span class="Italics">Postmarketing Trial:</span> In a postmarketing, multicenter, randomized, double-blind, parallel-group, clinical study in 848 cancer patients, the aprepitant regimen (N = 430) was compared with a standard of care therapy (N = 418) in patients receiving a moderately emetogenic chemotherapy regimen that included any IV dose of oxaliplatin, carboplatin, epirubicin, idarubicin, ifosfamide, irinotecan, daunorubicin, doxorubicin; cyclophosphamide IV (&lt;1500Â mg/m<span class="Sup">2</span>); or cytarabine IV (&gt;1 g/m<span class="Sup">2</span>).</p>
<p>Of the 430Â patients who were randomized to receive the aprepitant regimen, approximately 76% were women and 24% were men. The distribution by race was 67% White, 6% Black or African American, 11% Asian, and 12% multiracial. Classified by ethnicity, 36% were Hispanic and 64% were non-Hispanic. The aprepitant-treated patients in this clinical study ranged from 22 to 85Â years of age, with a mean age of 57Â years; approximately 59% of the patients were 55 years or older with 32Â patients being over 74Â years. Patients receiving the aprepitant regimen were receiving chemotherapy for a variety of tumor types including 50% with breast cancer, 21% with gastrointestinal cancers including colorectal cancer, 13% with lung cancer and 6% with gynecological cancers.</p>
<p>The antiemetic activity of EMEND was evaluated based on no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (with or without rescue therapy) in the overall period (0 to 120Â hours post-chemotherapy) and complete response (defined as no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and no use of rescue therapy) in the overall period.</p>
<p>A summary of the key results from this study is shown in TableÂ 10.</p>
<a name="id_44f34f34-9e6e-4d36-9567-86622b469814"></a><table width="691.000">
<caption><span>Table 10: Percent of Patients Receiving Moderately Emetogenic Chemotherapy Responding by Treatment Group for Study 2 â€” CycleÂ 1</span></caption>
<col width="30.2%">
<col width="24.6%">
<col width="24.6%">
<col width="20.5%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-26" href="#footnote-reference-26">*</a></dt>
<dd>N = Number of patients who received chemotherapy treatment, study drug, and had at least one post-treatment efficacy evaluation.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="justify" valign="top"><p class="First">ENDPOINTS</p></td>
<td class="Botrule" align="center" valign="top">
<p class="First">Aprepitant Regimen</p>
<p>(N = 430)<a name="footnote-reference-26" href="#footnote-26" class="Sup">*</a></p>%</td>
<td class="Botrule" align="center" valign="top">
<p class="First">Standard Therapy</p>
<p>(N = 418)<a href="#footnote-26" class="Sup">*</a></p>%</td>
<td class="Botrule" align="center" valign="top"><p class="First">p-Value </p></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Overall</td>
<td class="Botrule" align="center" valign="top">76</td>
<td class="Botrule" align="center" valign="top">62</td>
<td class="Botrule" align="center" valign="top">&lt;0.0001</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Complete Response Overall</td>
<td class="Botrule" align="center" valign="top">69</td>
<td class="Botrule" align="center" valign="top">56</td>
<td class="Botrule" align="center" valign="top">0.0003</td>
</tr>
</tbody>
</table>
<p>In this study, a statistically significantly higher proportion of patients receiving the aprepitant regimen (76%) in CycleÂ 1 had no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> during the overall phase compared with patients receiving standard therapy (62%). In addition, a higher proportion of patients receiving the aprepitant regimen (69%) in CycleÂ 1 had a complete response in the overall phase (0-120Â hours) compared with patients receiving standard therapy (56%). In the acute phase (0 to 24 hours following initiation of chemotherapy), a higher proportion of patients receiving aprepitant compared to patients receiving standard therapy were observed to have no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (92% and 84%, respectively) and complete response (89% and 80%, respectively). In the delayed phase (25 to 120 hours following initiation of chemotherapy), a higher proportion of patients receiving aprepitant compared to patients receiving standard therapy were observed to have no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (78% and 67%, respectively) and complete response (71% and 61%, respectively).</p>
<p>In a subgroup analysis by tumor type, a numerically higher proportion of patients receiving aprepitant were observed to have no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and complete response compared to patients receiving standard therapy. For gender, the difference in complete response rates between the aprepitant and standard regimen groups was 14% in females (64.5% and 50.3%, respectively) and 4% in males (82.2% and 78.2%, respectively) during the overall phase. A similar difference for gender was observed for the no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> endpoint.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a97e0db2-f0bd-4612-b99a-dd5f9774b326"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (PONV)</h2>
<p class="First">In two multicenter, randomized, double-blind, active comparator-controlled, parallel-group clinical studies (PONV Studies 1 and 2), aprepitant was compared with ondansetron for the prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in 1658 patients undergoing open abdominal surgery. Patients were randomized to receive 40 mg aprepitant, 125 mg aprepitant, or 4 mg ondansetron. Aprepitant was given orally with 50 mL of water 1 to 3 hours before anesthesia. Ondansetron was given intravenously immediately before induction of anesthesia. A comparison between the 125 mg dose and the 40 mg dose did not demonstrate any additional clinical benefit. The remainder of this section will focus on the results in the 40 mg aprepitant dose recommended for PONV.</p>
<p>Of the 564 patients who received 40 mg aprepitant, 92% were women and 8% were men; of these, 58% were White, 13% Hispanic American, 7% Multi-Racial, 14% Black, 6% Asian, and 2% Other. The age of patients treated with 40 mg aprepitant ranged from 19 to 84 years, with a mean age of 46.1 years. 46 patients were 65 years or older, with 13 patients being 75 years or older.</p>
<p>The antiemetic activity of EMEND was evaluated during the 0 to 48 hour period following the end of surgery. The two pivotal studies were of similar design; however, they differed in terms of study hypothesis, efficacy analyses and geographic location. PONV Study 1 was a multinational study including the U.S., whereas, PONV Study 2 was conducted entirely in the U.S.</p>
<p>Efficacy measures in PONV Study 1 included:</p>
<ul>
<li>no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (defined as no emetic episodes regardless of use of rescue therapy) in the 0 to 24 hours following the end of surgery (primary)</li>
<li>complete response (defined as no emetic episodes and no use of rescue therapy) in the 0 to 24 hours following the end of surgery (primary)</li>
<li>no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (defined as no emetic episodes regardless of use of rescue therapy) in the 0 to 48 hours following the end of surgery (secondary)</li>
<li>time to first use of rescue medication in the 0 to 24 hours following the end of surgery (exploratory)</li>
<li>time to first <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> in the 0 to 48 hours following the end of surgery (exploratory).</li>
</ul>
<p>A closed testing procedure was applied to control the type I error for the primary endpoints. </p>
<p>The results of the primary and secondary endpoints for 40 mg aprepitant and 4 mg ondansetron are described in Table 11:</p>
<a name="id_7b36857e-0a66-4bdf-abda-4261a7b328ce"></a><table width="642.000">
<caption><span>Table 11: PONV Study 1 â€“ Response Rates for Select Efficacy Endpoints (Modified-Intention-to-Treat Population)</span></caption>
<col width="39.4%">
<col width="21.3%">
<col width="10.3%">
<col width="14.5%">
<col width="14.5%">
<tfoot>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="5" valign="top">n/m = Number of responders/number of patients in analysis.<br>Î” Difference (%): Aprepitant 40 mg minus Ondansetron.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-27" href="#footnote-reference-27">*</a></dt>
<dd>Estimated odds ratio for Aprepitant versus Ondansetron. A value of &gt;1 favors Aprepitant over Ondansetron.</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">â€ </a></dt>
<dd>P-value of two-sided test &lt;0.05.</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">â€¡</a></dt>
<dd>LB= lower bound of 1-sided 97.5% confidence interval for the odds ratio.</dd>
<dt><a name="footnote-30" href="#footnote-reference-30">Â§</a></dt>
<dd>Based on the prespecified fixed sequence multiplicity strategy, Aprepitant 40 mg was not superior to Ondansetron.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" rowspan="2" valign="top"><span class="Bold">Treatment </span></td>
<td class="Botrule" align="center" rowspan="2" valign="top"><span class="Bold">n/m (%)</span></td>
<td class="Botrule" align="center" colspan="3" valign="top">
<span class="Bold">Aprepitant</span><br><span class="Bold">vs</span><br><span class="Bold">Ondansetron</span>
</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top"><span class="Bold">Î”</span></td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">Odds</span><br><span class="Bold"> ratio<a name="footnote-reference-27" href="#footnote-27" class="Sup">*</a></span>
</td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Analysis</span></td>
</tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top"><span class="Bold">Primary Endpoints</span></td></tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </span>0 to 24 hours (Superiority)<br>(no emetic episodes)</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Aprepitant 40 mg</td>
<td class="Botrule" align="center" valign="top">246/293 (84.0)</td>
<td class="Botrule" align="center" valign="top">12.6%</td>
<td class="Botrule" align="center" valign="top">2.1</td>
<td class="Botrule" align="center" valign="top">P&lt;0.001<a name="footnote-reference-28" href="#footnote-28" class="Sup">â€ </a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ondansetron</td>
<td class="Botrule" align="center" valign="top">200/280 (71.4)</td>
<td class="Botrule" align="center" colspan="3" valign="top"></td>
</tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">Complete Response</span> (Non-inferiority: If LB<a name="footnote-reference-29" href="#footnote-29" class="Sup">â€¡</a> &gt;0.65)<br>(no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and no rescue therapy, 0 to 24 hours)</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Aprepitant 40 mg</td>
<td class="Botrule" align="center" valign="top">187/293 (63.8)</td>
<td class="Botrule" align="center" valign="top">8.8%</td>
<td class="Botrule" align="center" valign="top">1.4</td>
<td class="Botrule" align="center" valign="top">LB=1.02</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ondansetron</td>
<td class="Botrule" align="center" valign="top">154/280 (55.0)</td>
<td class="Botrule" align="center" colspan="3" valign="top"></td>
</tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">Complete Response</span> (Superiority: If LB &gt;1.0)<br>(no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and no rescue therapy, 0 to 24 hours)</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Aprepitant 40 mg</td>
<td class="Botrule" align="center" valign="top">187/293 (63.8)</td>
<td class="Botrule" align="center" valign="top">8.8%</td>
<td class="Botrule" align="center" valign="top">1.4</td>
<td class="Botrule" align="center" valign="top">LB=1.02<a name="footnote-reference-30" href="#footnote-30" class="Sup">Â§</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ondansetron</td>
<td class="Botrule" align="center" valign="top">154/280 (55.0)</td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top"><span class="Bold">Secondary Endpoint</span></td></tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span> 0 to 48 (Superiority)<br>(no emetic episodes)</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Aprepitant 40 mg</td>
<td class="Botrule" align="center" valign="top">238/292 (81.5)</td>
<td class="Botrule" align="center" valign="top">15.2%</td>
<td class="Botrule" align="center" valign="top">2.3</td>
<td class="Botrule" align="center" valign="top">P&lt;0.001<a href="#footnote-28" class="Sup">â€ </a>
</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Ondansetron</td>
<td align="center" valign="top">185/279 (66.3)</td>
<td align="left" colspan="3" valign="top"></td>
</tr>
</tbody>
</table>
<p>The use of aprepitant did not affect the time to first use of rescue medication when compared to ondansetron. However, compared to the ondansetron group, use of aprepitant delayed the time to first <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, as depicted in Figure 3.</p>
<div class="Figure">
<img alt="image of figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec44482e-6194-4829-a3f7-ebe8d48a41a5&amp;name=ec44482e-6194-4829-a3f7-ebe8d48a41a5-04.jpg"><p class="MultiMediaCaption">Figure 3: Percent of Patients Who Remain <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> Free During the 48 Hours Following End of Surgery</p>
</div>
<p>Efficacy measures in PONV Study 2 included:</p>
<ul>
<li>complete response (defined as no emetic episodes and no use of rescue therapy) in the 0 to 24 hours following the end of surgery (primary)</li>
<li>no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (defined as no emetic episodes regardless of use of rescue therapy) in the 0 to 24 hours following the end of surgery (secondary)</li>
<li>no use of rescue therapy in the 0 to 24 hours following the end of surgery (secondary)</li>
<li>no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (defined as no emetic episodes regardless of use of rescue therapy) in the 0 to 48 hours following the end of surgery (secondary).</li>
</ul>
<p>PONV Study 2 failed to satisfy its primary hypothesis that aprepitant is superior to ondansetron in the prevention of PONV as measured by the proportion of patients with complete response in the 24 hours following end of surgery.</p>
<p>The study demonstrated that both dose levels of aprepitant had a clinically meaningful effect with respect to the secondary endpoint â€œno vomitingâ€? during the first 24 hours after surgery and showed that the use of 40Â mg aprepitant was associated with a 16% improvement over ondansetron for the no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> endpoint.</p>
<a name="id_713d5d37-0cb9-4c4b-a9fa-6affa2908e68"></a><table width="654.000">
<caption><span>Table 12: PONV Study 2 (Modified-Intention-to-Treat Population)</span></caption>
<col width="31.0%">
<col width="20.2%">
<col width="15.1%">
<col width="16.8%">
<col width="16.8%">
<tfoot>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="5" valign="top">n/m = Number of responders/number of patients in analysis.<br>Î” Difference (%): Aprepitant 40 mg minus Ondansetron.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-31" href="#footnote-reference-31">*</a></dt>
<dd>Estimated odds ratio: Aprepitant 40 mg versus Ondansetron.</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">â€ </a></dt>
<dd>Not statistically significant after pre-specified multiplicity adjustment.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" rowspan="2" valign="top"><span class="Bold">Treatment</span></td>
<td class="Botrule" align="center" rowspan="2" valign="top">
<span class="Bold">n/m</span><span class="Bold">(%)</span>
</td>
<td class="Botrule" align="center" colspan="3" valign="top"><span class="Bold">Aprepitant <br> vs <br> Ondansetron</span></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top"><span class="Bold">Î”</span></td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">Odds <br> ratio</span><a name="footnote-reference-31" href="#footnote-31" class="Sup">*</a>
</td>
<td class="Botrule" align="center" valign="top"><span class="Bold">p-Value</span></td>
</tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top"><span class="Bold">Primary Endpoint</span></td></tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">Complete Response </span><br>(no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and no rescue therapy, 0 to 24 hours)</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Aprepitant 40 mg</td>
<td class="Botrule" align="center" valign="top">111/248 (44.8)</td>
<td class="Botrule" align="center" valign="top">2.5%</td>
<td class="Botrule" align="center" valign="top">1.1 </td>
<td class="Botrule" align="center" valign="top"> 0.61</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ondansetron</td>
<td class="Botrule" align="center" valign="top">104/246 (42.3)</td>
<td class="Botrule" align="center" colspan="3" valign="top"></td>
</tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top"><span class="Bold">Secondary Endpoints</span></td></tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span><br> (no emetic episodes, 0 to 24 hours)</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Aprepitant 40 mg</td>
<td class="Botrule" align="center" valign="top">223/248 (89.9)</td>
<td class="Botrule" align="center" valign="top">16.3%</td>
<td class="Botrule" align="center" valign="top">3.2</td>
<td class="Botrule" align="center" valign="top">&lt;0.001<a name="footnote-reference-32" href="#footnote-32" class="Sup">â€ </a>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ondansetron</td>
<td class="Botrule" align="center" valign="top">181/246 (73.6)</td>
<td class="Botrule" align="center" colspan="3" valign="top"></td>
</tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">No Use of Rescue Medication</span><br> (for established <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 0 to 24 hours)</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Aprepitant 40 mg</td>
<td class="Botrule" align="center" valign="top">112/248 (45.2)</td>
<td class="Botrule" align="center" valign="top">-0.7%</td>
<td class="Botrule" align="center" valign="top">1.0</td>
<td class="Botrule" align="center" valign="top">0.83</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Ondansetron</td>
<td class="Botrule" align="center" valign="top">113/246 (45.9)</td>
<td class="Botrule" align="center" colspan="3" valign="top"></td>
</tr>
<tr><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </span>0 to 48 (Superiority) <br>(no emetic episodes, 0 to 48 hours)</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Aprepitant 40 mg</td>
<td class="Botrule" align="center" valign="top">209/247 (84.6)</td>
<td class="Botrule" align="center" valign="top">17.7%</td>
<td class="Botrule" align="center" valign="top">2.7</td>
<td class="Botrule" align="center" valign="top">&lt;0.001<a href="#footnote-32" class="Sup">â€ </a>
</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Ondansetron</td>
<td align="center" valign="top">164/245 (66.9)</td>
<td align="center" colspan="3" valign="top"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_330d740f-d7c2-403b-b0af-bd831ce68d78"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">No.Â 6741Â â€” 40Â mg capsules: Opaque, hard gelatin capsule with white body and mustard yellow cap with â€œ464â€? and â€œ40Â mgâ€? printed radially in black ink on the body. They are supplied as follows:</p>
<p><span class="Bold">NDC</span>Â 42254-160-01 unit-of-use package of 1 </p>
<p><span class="Italics">Storage</span></p>
<p>Store at 20-25Â°C (68-77Â°F) [see USP Controlled Room Temperature].</p>
<p><br>Merck Sharp &amp; Dohme Corp., a subsidiary of <br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>9988902</p>
<p>U.S. Patent Nos.: 5,145,684; 5,719,147; 6,048,859; 6,096,742; 6,235,735</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_4cef9ee8-9fbd-4c3f-bd29-d07b694ec7bd"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">[See <a href="#i4i_info_patients_id_4cef9ee8-9fbd-4c3f-bd29-d07b694ec7bd">FDA-Approved Patient Labeling</a>.]</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5e55651-f2c2-4d68-ac62-3cae93ea603a"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Instructions</h2>
<p class="First">Physicians should instruct their patients to read the patient package insert before starting therapy with EMEND and to reread it each time the prescription is renewed.</p>
<p>Patients should be instructed to take EMEND only as prescribed. For the prevention of chemotherapy induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (CINV), patients should be advised to take their first dose (125 mg) of EMEND 1 hour prior to chemotherapy treatment. For the prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (PONV), patients should receive their medication (40 mg capsule of EMEND) within 3 hours prior to induction of anesthesia. </p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>, which may be serious, and may include <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and cause difficulty in breathing or swallowing, have been reported in general use with EMEND. Physicians should instruct their patients to stop taking EMEND and call their doctor right away if they experience an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. In addition, severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur rarely.</p>
<p>EMEND may interact with some drugs including chemotherapy; therefore, patients should be advised to report to their doctor the use of any other prescription, non-prescription medication or herbal products.</p>
<p>Patients on chronic warfarin therapy should be instructed to have their clotting status closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of EMEND 125Â mg/80Â mg with each chemotherapy cycle, or following administration of a single 40Â mg dose of EMEND for the prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Administration of EMEND may reduce the efficacy of hormonal contraceptives. Patients should be advised to use alternative or back-up methods of contraception during treatment with EMEND and for 1 month following the last dose of EMEND.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_2b8ebba0-cdb6-453d-af61-a46101f8c16e"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling</span></p>
<p><span class="Bold">Patient Information<br>EMENDÂ® (EE mend)<br>(aprepitant)<br>Capsules</span></p>
<p>Read the Patient Information that comes with EMEND before you start taking it and each time you refill your prescription. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment.</p>
<p><span class="Bold">What is EMEND?</span></p>
<p>EMEND is a prescription medicine used in adults to prevent <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>: </p>
<ul>
<li>caused by certain anti-cancer (chemotherapy) medicines. When used for this purpose, EMEND is always used with other medicines.</li>
<li>after surgery.</li>
</ul>
<p>EMEND is not used to treat <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that you already have.</p>
<p>EMEND should not be used continuously for a long time (chronic use). </p>
<p>It is not known if EMEND is safe and effective in children. </p>
<p><span class="Bold">Who should not take EMEND?</span></p>
<p><span class="Bold">Do not take EMEND if you:</span></p>
<ul><li>are taking any of the following medicines: <ul>
<li>ORAPÂ® (pimozide)</li>
<li>SELDANEÂ® (terfenadine)</li>
<li>HISMANALÂ® (astemizole)</li>
<li>PROPULSIDÂ® (cisapride)<br>
</li>
</ul>
</li></ul>
<p> Taking EMEND with any of these medicines could cause serious or life-threatening problems.<br></p>
<ul><li>are allergic to any of the ingredients in EMEND. See the end of this leaflet for a list of all the ingredients in EMEND.</li></ul>
<p><span class="Bold">What should I tell my doctor before and during treatment with EMEND?</span></p>
<p><span class="Bold">Before you take EMEND, tell your doctor if you:</span></p>
<ul>
<li>have liver problems</li>
<li>are pregnant or plan to become pregnant. It is not known if EMEND can harm your unborn baby.<br><br> Women who use birth control medicines containing hormones to prevent pregnancy (birth control pills, skin patches, implants, and certain IUDs) should also use a back-up method of birth control during treatment with EMEND and for up to 1 month after using EMEND to prevent pregnancy. <br><br>
</li>
<li>are breast-feeding. It is not known if EMEND passes into your milk and if it can harm your baby.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you are taking or plan to take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements. </p>
<p><span class="Bold">EMEND may cause serious life-threatening reactions if used with certain medicines. See the section â€œWho should not take EMEND?" </span></p>
<p>EMEND may affect how other medicines work, and other medicines may affect how EMEND works. Ask your doctor or pharmacist before you take any new medicine. They can tell you if it is safe to take the medicine with EMEND.</p>
<p>Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take EMEND?</span></p>
<ul>
<li>Take EMEND exactly as prescribed.</li>
<li>If you take too much EMEND, call your doctor, local emergency department or poison control center right away.<br><br>
</li>
<li>If you are receiving cancer chemotherapy, EMEND is taken as 3 doses over 3 days - starting on the day you have chemotherapy, and the two days after chemotherapy. There are two ways that your doctor may prescribe EMEND for you:</li>
</ul>
<ol>
<li> Capsules of EMEND by mouth for all 3 doses: <ul>
<li>You should get a package that has three capsules of EMEND.</li>
<li> Day 1 (Day of chemotherapy): Take one 125-mg capsule of EMEND (white and pink) by mouth 1 hour before you start your chemotherapy treatment.</li>
<li> Day 2 and Day 3 (the two days after chemotherapy): Take one 80-mg capsule of EMEND (white) by mouth, each morning for the 2Â days after your chemotherapy treatment.<br><br> Or <br><br>
</li>
</ul>
</li>
<li> Intravenous (IV) injection into a vein the first day, then capsules by mouth on the two days after chemotherapy: <ul>
<li> Day 1 (Day of chemotherapy): EMEND will be given to you by intravenous (IV) injection in your vein 30 minutes before you start your chemotherapy treatment.</li>
<li>You should get a package that has two capsules of EMEND.</li>
<li> Day 2 and Day 3 (the two days after chemotherapy): Take one 80-mg capsule of EMEND (white) by mouth, each morning for the 2Â days after your chemotherapy treatment.</li>
</ul>
</li>
</ol>
<ul>
<li>If you are receiving chemotherapy, EMEND may be taken with or without food.</li>
<li> If you are having surgery: <br><br><ul>
<li>Your doctor will prescribe a 40-mg capsule of EMEND for you before surgery. You take EMEND within three hours before surgery.</li>
<li>Follow your doctorâ€™s instructions about restrictions on eating and drinking before surgery.<br><br>
</li>
</ul>
</li>
<li>If you take the blood thinner medicine warfarin sodium (COUMADINÂ®, JANTOVENÂ®), your doctor may do blood tests after you take EMEND to check your blood clotting.</li>
</ul>
<p><span class="Bold">What are the possible side effects of EMEND?</span></p>
<p><span class="Bold">EMEND may cause serious side effects, </span>including: <br></p>
<ul>
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> can happen with EMEND and may be serious. Stop taking EMEND and call your doctor right away if you have any of these signs or symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>: <ul>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> </li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> </li>
<li>trouble breathing or swallowing.</li>
</ul>
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur rarely. </li>
</ul>
<p>In people taking EMEND to prevent <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> caused by chemotherapy, the most common side effects of EMEND include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>loss of appetite</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span></li>
</ul>
<p>In people taking EMEND to prevent <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> after surgery, the most common side effects are:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of EMEND. For more information ask your doctor or pharmacist. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store EMEND?</span></p>
<ul>
<li>Store EMEND at room temperature, between 68Â°F and 77Â°F (20Â°CÂ and 25Â°C).</li>
<li><span class="Bold">Keep EMEND and all medicines out of the reach of children.</span></li>
</ul>
<p><span class="Bold"> General information about EMEND </span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use EMEND for a condition for which it was not prescribed. Do not give EMEND to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about EMEND. If you would like to know more information, talk with your doctor. You can ask your doctor or pharmacist for information about EMEND that is written for health professionals. For more information about EMEND call 1-800-622-4477 or go to <a href="http://www.emend.com/">www.emend.com</a>.</p>
<p><span class="Bold">What are the ingredients in EMEND?</span></p>
<p><span class="Bold">Active ingredient:</span> aprepitant</p>
<p><span class="Bold">Inactive ingredients:</span> sucrose, microcrystalline cellulose, hydroxypropyl cellulose and sodium lauryl sulfate. The capsule shell excipients are gelatin, titanium dioxide, and may contain sodium lauryl sulfate and silicon dioxide. The 125-mg capsule shell also contains red ferric oxide and yellow ferric oxide. The 40-mg capsule shell also contains yellow ferric oxide.</p>
<p><br>U.S. Patent Nos.: 5,145,684; 5,719,147; 6,048,859; 6,096,742; 6,235,735</p>
<p><br>The brands listed in the above sections â€œWho should not take EMEND?â€? and â€œWhat should I tell my doctor before and during treatment with EMEND?â€? are the registered trademarks of their respective owners and are not trademarks of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.</p>
<p>EMEND<span class="Sup">Â®</span> is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.<br></span>Copyright Â© 2003, 2005, 2006 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.<br></span>All rights reserved</p>
<p> Issued March 2011</p>
<p>Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.<br>Whitehouse Station, NJ 08889, USA </p>
<p>9988902</p>
<p><br>Repackaged by:</p>
<p>Rebel Distributors Corp<br>Thousand Oaks, CA 91320</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0cefd7c5-0f01-4462-9518-738acada7040"></a><a name="section-17"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First"><img alt="Emend 40mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec44482e-6194-4829-a3f7-ebe8d48a41a5&amp;name=ec44482e-6194-4829-a3f7-ebe8d48a41a5-05.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EMENDÂ 		
					</strong><br><span class="contentTableReg">aprepitant capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42254-160(NDC:0006-0464)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>aprepitant</strong> (aprepitant) </td>
<td class="formItem">aprepitant</td>
<td class="formItem">40Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydroxypropyl cellulose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (opaque, white) ,Â YELLOW (opaque, mustard yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (capsule) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">464;40;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42254-160-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021549</td>
<td class="formItem">03/26/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Rebel Distributors Corp
							(118802834)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rebel Distributors Corp</td>
<td class="formItem"></td>
<td class="formItem">118802834</td>
<td class="formItem">RELABEL, REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ec44482e-6194-4829-a3f7-ebe8d48a41a5</div>
<div>Set id: ec44482e-6194-4829-a3f7-ebe8d48a41a5</div>
<div>Version: 1</div>
<div>Effective Time: 20120223</div>
</div>
</div>Â <div class="DistributorName">Rebel Distributors Corp</div></p>
</body></html>
